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Abstract 
A drug delivery system is an essential tool for improving drug therapies by 
overcoming the limitations of ‘free’ drug delivery including low solubility in water, 
poor stability in biological systems, short residence time, unspecific toxicity and side 
effects. Nowadays, nanomaterials have become ideal vehicles for drug delivery 
owing to their very small size and high surface-to-volume ratio. Their small size 
ensures access to different biological tissues, efficient cellular uptake and facilitates 
intracellular delivery of therapeutics. Their high surface area allows for high drug 
loading and the attachment of various functional groups. Among various 
nanomaterials, mesoporous silica nanoparticles show great potential for delivery 
application due to their good biocompatibility, well-developed mesoporosity, and 
versatile surface functionalization. However, to construct an efficient delivery system, 
the primary silica nanoparticles still need to be optimized in structure to load large 
biomolecules and modified in surface chemistry to achieve efficient targeting and 
release control. 
 With this aim, this Ph.D thesis has demonstrated the design and fabrication of a 
serial of novel mesoporous silica based nanocomposites as drug and gene delivery 
carriers. These researches include: 
 (1) We firstly studied the controllable synthesis of stellate mesoporous silica 
nanoparticles with radial pore morphology. By using triethanolamine as the base 
catalyst and adjusting the surfactant composition, reaction temperature and time, 
and reagent ratio, we demonstrated that the particle size of these nanomaterials 
could be tailored continuously from 50 to 140 nm and the pore size could be tuned 
from 2 to 20 nm, respectively. After further functionalization with low molecular 
weight poly(ethyleneimine), these nanocomposites demonstrated good capability 
for intracellular delivery of the anticancer drug doxorubicin. 
 (2) Then, we developed a cancer cell-specific nuclear-targeted delivery system 
based on mesoporous silica nanoparticles. Mesoporous silica nanoparticles with 40 
nm particle size were modified with dual targeting ligands, i.e., folic acid for cancer 
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cell targeting and dexamethasone for nuclear targeting. The resulting nanocarriers 
could not only enhance the inhibition efficacy of doxorubicin on cancerous Hela cells 
through active nucleus accumulation but also reduce toxic side effects on normal 
cells though receptor-mediated selective cellular uptake. 
 (3) Next, we studied magnetic core–shell silica nanoparticles with large radial 
mesopores for small interfering RNA (siRNA) delivery. These nanoparticles possess 
both high loading capacity of siRNA and strong magnetic response under an external 
magnetic field. Furthermore, an acid-liable coating composed of tannic acid was 
applied to further protect the siRNA loaded in the large pores. The coating also 
increased the dispersion stability of the siRNA-loaded carrier and served as a 
pH-responsive releasing switch. Using these nanocarriers, enhanced delivery of 
functional siRNA into human osteosarcoma cancer cells was achieved with the aid of 
the external magnetic field. 
 (4) Finally, we prepared bowl-like mesoporous organosilica nanoparticles for 
DNA delivery. The nanoparticles were prepared by a simple “hard templating 
followed by hydrothermal etching” method. After amine functionalization, these 
nano-bowls showed significantly higher loading capacity for plasmid DNA than 
traditional structured (hollow, dendric, MCM41 type) silica-based nanocarriers 
thanks to their large accessible center cavity. Furthermore, after co-loading with an 
endosomolytic reagent in the mesopores, enhanced transfection efficiency 
comparable to the polymer standard was achieved for in vitro plasmid DNA 
transfection. 
 In summary, these findings have demonstrated the design and fabrication of 
several novel silica nanocomposties for drug and gene delivery, provided a deeper 
understanding of the relationship between the physicochemical properties of silica 
nanocomposties and their bioactivity, and may pave a way of the further 
development of silica-based delivery system.
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Chapter 1 Introduction 
1.1 Background and significance 
Nowadays, the rapid advancement of nanotechnology and nanomaterial science are 
revolutionizing the world of medical therapy.[1] For example, the size- and 
shape-dependent optical and electronic properties of gold nanoparticles have led to 
their wide applications in biological diagnosis and photothermal therapy.[2, 3] 
Magnetic nanoparticles have been extensively investigated for magnetic resonance 
imaging (MRI), hyperthermia, magnetic field-targeted delivery, and protein 
separation.[4, 5] These applications of nanotechnology and nanomaterials for 
treatment, diagnosis, monitoring, and control of biological systems have been 
named as “nanomedicine” by the National Institutes of Health.[6] 
 In nanomedicine, drug delivery applications plays a dominate role, accounting 
for about three-quarters of the research activity and of the nanomedicine market.[1] 
An important reason for this is the great potential of nanosized drug carriers to 
address one of the most pressing threats for current human society - cancer.[7] These 
nanocarriers are expected to overcome limitations associated with conventional 
chemotherapy drug formulations, surmount various biological barriers and deliver 
drugs precisely to the cancer sites.[8] A typical successful example is the liposomal 
doxorubicin (Doxil), which was approved by the US Food and Drug Administration for 
the treatment of Kaposi's sarcoma.[9] In contrast to the free doxorubicin drug which 
has dangerous dose-dependent cardiotoxicity, the liposome encapsulated drug 
shows an equivalent efficacy and improved safety profile. Thus, these 
nanomaterial-based delivery systems could provide new application opportunities 
for traditional drugs to reduce the side effects.[10] Meanwhile, with the development 
of biotechnology, there is also considerable interest in exploiting the nanocarriers for 
delivery of new drugs including therapeutic proteins and genes.[11, 12] As the origins 
of many diseases including cancer are related to genetic defection and mutation, 
gene therapy has been considered as a promising therapeutic method by delivering 
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foreign nucleic acids (DNA, RNA, and oligonucleotides) into living cells.[13] Because 
gene molecules are much larger in size and less stable than common small molecule 
drugs, nanocarriers with special particle structure and surface chemistry need to be 
developed for their delivery. 
 So far, different formulations of nanomaterials have been explored for drug 
delivery purpose. These include liposomes, polymer micelles, emulsions, polymer 
nanogels and inorganic particles (gold, carbon, iron oxide, silica, etc.). The unique 
advantages of mesoporous silica nanocomposites are highly developed porosity, 
well-defined morphology, versatile functionalization and good biocompatibility.[14-18] 
1.2 Objective and thesis outline 
The objective of this project is to design and fabricate a serial of novel mesoporous 
silica nanocomposites with favorable structure and surface functionalization as drug 
and gene delivery nanocarriers. The main achievements obtained in this thesis are 
presented in the form of four published papers in peer-reviewed journals. The 
following chapters in this thesis are organized according to the sequence below: 
 In chapter 2, a literature review on the synthesis, functionalization and delivery 
application of mesoporous silica nanocomposites is given. 
 In chapter 3, tunable stellate mesoporous silica nanoparticles with radial pore 
morphology were synthesized using triethanolamine as the base catalyst. By 
adjusting the surfactant composition, reaction temperature and time, and reagent 
ratio, the particle size of the material could be tailored continuously ranging from 50 
to 140 nm and the pore size from 2 to 20 nm. After functionalization with low 
molecular weight poly(ethyleneimine), these nanocomposites demonstrated good 
potential for intracellular delivery of the anticancer drug doxorubicin. This 
investigation has been published in J. Mater. Chem. B, 2015, 3, 1712. 
 In chapter 4, mesoporous silica nanoparticles with 40 nm particle size were 
modified with dual targeting ligands, i.e., folic acid and dexamethasone, to construct 
a cancer-cell-specific nuclear-targeted delivery system. The resulting nanocarriers 
not only enhanced the inhibition efficacy of doxorubicin on cancerous Hela cells 
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through active nucleus accumulation but also reduced toxic side effects on normal 
cells though receptor mediated selective cellular uptake. This investigation has been 
published in Small, 2015, 11, 5919. 
 In chapter 5, magnetic core–shell silica nanoparticles were developed for small 
interfering RNA (siRNA) delivery. These nanoparticles were fabricated by coating 
super-paramagnetic magnetite nanocrystal clusters with radial large-pore 
mesoporous silica. These nanoparticles possess both high loading capacity of siRNA 
and strong magnetic response under an external magnetic field. An acid-liable 
coating composed of tannic acid further protected the siRNA loaded in these 
nanoparticles. The coating also increased the dispersion stability of the siRNA-loaded 
carrier and served as a pH-responsive releasing switch. Using the magnetic silica 
nanoparticles with tannic acid coating as carriers, enhanced delivery of functional 
siRNA into human osteosarcoma cancer cells was achieved with the aid of the 
external magnetic field. This investigation has been published in Small, 2016, 12, 
4735. 
 In chapter 6, bowl-like mesoporous organosilica nanoparticles were prepared for 
the first time by a simple “hard templating followed by hydrothermal etching” 
method. After amine functionalization, these nano-bowls showed significantly higher 
loading capability for plasmid DNA than traditional (hollow, dendric, MCM41 type) 
silica-based nanocarriers thanks to their large accessible center cavity. Furthermore, 
after co-loading with an endosomolytic reagent in the mesopores, enhanced 
transfection efficiency comparable to the polymer standard was achieved for in vitro 
plasmid DNA transfection. This investigation has been published in Nanoscale, 2016, 
8, 17446. 
 In chapter 7, a general summary of the results in this thesis and a brief 
discussion on future directions of the work are presented. 
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Chapter 2 Literature Review 
2.1 Introduction 
2.1.1 Drug delivery system 
Nowadays, the development of medical treatments is driving the evolution of 
therapeutic agents and also the delivery method. Many drugs can not be 
administered directly due to their low solubility in water, poor stability in biological 
systems, short residence time, unspecific toxicity and side effects.[1] A drug delivery 
system (DDS) is expected to overcome the limitations of ‘free’ drugs and can be 
described as a formulation that controls the release rate and period of drug to 
specific parts in the body. A well-designed DDS is an essential tool for improving 
current therapies by manipulating the biological profiles of therapeutics, such as 
pharmacokinetics, biodistribution, tissue uptake, and so on. To this end, the ideal 
DDS should meet several strict requirements simultaneously: 1) biocompatibility, 2) 
high loading and protection of the therapeutics, 3) efficient targeting, 4) no 
premature release, 5) efficient cellular uptake, and 6) controllable release.[2, 3] 
Therefore, the construct of an effective DDS is one of the major challenges of 
medicine today. 
 With the development of nanomaterials and nanotechnology, nanoparticulate 
drug carriers may provide a solution to the above challenge. Due to the small size of 
nanoparticles, they can penetrate various physiological barriers and access different 
tissues, cells and even sub-cellular compartments.[4, 5] Meanwhile, the small size of 
nanoparticles also lead to a high surface-to-mass ratio, which means they have a 
large surface area to bind, adsorb and carry drugs, or to conjugate with various 
functional moieties such as targeting ligands.[6] Furthermore, distinct from most of 
the molecular delivery system, nanoparticulate carriers can be constructed into a 
multifunctional platform which can not only co-deliver multiple therapeutic agents 
but also provide additional theranostic functions, such as diagnostic imaging, 
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photothermal therapy, and photodynamic therapy. Until now, various types of 
nanoparticles, such as lipid, polymer, carbon, gold, iron oxide, metal–organic 
framework, quantum dot, upconversion nanocrystal and silica, have been 
investigated for drug delivery applications (Fig. 1).[7] 
 
Fig. 1 Various nanoparticulate carriers: (a) polymeric nanogel, (b) polymeric micelle, 
(c) gold nanoparticle, (d) iron oxide nanoparticle, (e) siRNA in a liposome delivery 
vector, and (f) a stimuli-responsive capped mesoporous silica nanoparticles. 
Reproduced from Ref. [7] with permission. Copyright (2012) The Royal Society of 
Chemistry. 
2.1.2 Mesoporous silica nanoparticles 
In the last decade, mesoporous silica nanoparticles (MSNs) (Fig. 2) have emerged as 
one of the most promising nanomaterials for drug delivery.[8-11] This is due to their 
unique flexibility, versatility and stability compared with other platforms. Firstly, the 
flexible and relatively low-cost fabrication of MSNs is highly suitable for scalable 
production and clinical translation. Secondly, the structural parameters of MSNs can 
be tailored in a wide range, such as particle morphologies (sphere, rod, hollow, 
rattle-type, etc.), particle sizes (20-250 nm), pore structure and pore sizes (2-40 nm). 
Thirdly, the surface of MSNs can be facilely modified by various organic moieties or 
conjugated with other nanostructures to satisfy the particular requirements of a 
specific application. Finally, silica materials are generally biocompatible and could be 
degraded or excreted from human body eventually. 
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Fig. 2 Typical scanning electron microscopy (SEM) (a) and transmission electron 
microscopy (TEM) (b) images of MCM-41 mesoporous silica nanoparticles. 
Reproduced from Ref. [7] with permission. Copyright (2012) The Royal Society of 
Chemistry. 
2.2 Particle synthesis 
2.2.1 Synthesis mechanism 
Mesoporous materials are classified as having a pore diameter between 2 and 50 nm 
following the recommendation by International Union of Pure and Applied Chemistry 
(IUPAC). The first reported and most common class of mesoporous silica materials is 
Mobil composite material number 41 (MCM-41) developed by the Mobil Oil 
Company in 1992, which is characterized by a hexagonal array of uniformly sized 
one-dimensional mesopores.[12] The formation of mesoporous silica materials 
involves hydrolysis and condensation of silica precursors (e.g., silicic acid, Si(OH)4, or 
polysilicic acids) in the presence of structure directing agents (SDA), commonly 
amphiphilic surfactants. In a typical synthesis, the amphiphilic surfactant molecules 
assemble into complex liquid crystal structures above the critical micelle 
concentration or through interaction with silica species.[13] Then the silica species 
concentrate at the hydrophilic interface of SDA through electrostatic attraction or 
hydrogen bonding and condense to form an amorphous silica framework. The final 
mesoporous silica product is obtained after the removal of surfactant template by 
extraction or calcination. Fig. 3 shows the formation pathways for MCM-41. 
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Fig. 3 Formation of mesoporous materials by structure-directing agents: a) true 
liquid crystal template mechanism, b) cooperative liquid crystal template mechanism. 
Reproduced from Ref. [13] with permission. Copyright (2006) John Wiley and Sons. 
2.2.2 Particle size 
In its first introduction, MCM-41 appeared as micrometer-sized, amorphous 
aggregates. Till now, the modified procedure has enabled the synthesis of MSNs with 
monodisperse particle size as small as 25 nm.[14] For instance, Fig. 4 shows that the 
particle size of mesoporous silica could be adjusted from 30 to 280 nm by controlling 
the synthesis pH. The drastic reduction in particle size and improvement in size 
polydispersity facilitate the application of these nanoparticles for biological 
purposes.[11] The prerequisite for size control of MSNs involves controlling the 
hydrolysis and condensation rates of the silica sources, which are highly associated 
with several factors such as reaction pH, silica source, solvent, additives, and 
temperature.[15] Among various factors, Chiang et al. demonstrated that pH has the 
largest influence rather than the amount of silica source and reaction time on the 
control of particle sizes of MSNs.[16] 
 For drug delivery application, a control over the particle size is important 
because the size has an influence on the biodistribution,[17] cellular uptake,[18] 
nucleus entering[19] and biocompatibility[14] of MSNs. For example, in order to 
achieve passive accumulation of the drug carriers inside tumor tissues via the 
enhanced permeation and retention (EPR) effect,[20] a particle diameter between 30 
nm and 150 nm is desired. It is also found that the uptake of MSNs by HeLa cells is 
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particle-size-dependent from 30 to 280 nm, and the maximum uptake occurred at 
the nanoparticle size of 50 nm.[18] 
 
Fig. 4 TEM images of mesoporous silica with different average sizes: a) 280 nm; inset: 
FFT analysis of the TEM image; b) 170 nm, c) 110 nm, d) 50 nm, e) 30 nm. f) 
High-resolution TEM image of a single particle in (c). Reproduced from Ref. [18] with 
permission. Copyright (2009) John Wiley and Sons. 
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2.2.3 Particle morphology 
By tailoring the molar ratio between silica precursors and surfactants, pH control, 
addition of co-solvents or organic swelling agents, and introduction of 
organoalkoxysilane precursors during the co-condensation reaction, the particle 
morphology of MSNs can be varied from sphere, rod, to wormlike structures.[10] Cai 
and co-workers studied factors affecting the morphology of MCM-41 type MSNs and 
concluded that the morphology of the particle is determined by the type of catalyst 
used.[21] More specifically, NH4OH leads to a rod-like morphology, while NaOH forms 
short and smaller size micelles, making the particles spherical. Furthermore, hollow 
MSNs can be fabricated by various templating methods, such as hard-templating,[22] 
vesicle-templating,[23] microemulsion-templating,[24] and selective etching[25-27]. 
Recently, more complex structures such as multi-shelled hollow nanospheres,[28] 
yolk-shell nanoparticles[29], dendric nanoparticles,[30] and Janus-type nanoparticles[31] 
have also been reported. Fig. 5 shows the structural development of spherical silica 
nanoparticles.[32] 
 
Fig. 5 Structural evolution of spherical silica micro/nanomaterials. Reproduced from 
Ref. [32] with permission from The Royal Society of Chemistry. 
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 Particle morphology has a great influence on the loading capability of MSNs. 
Hollow MSNs have been reported to show high loading capacity of anti-cancer drugs 
and therapeutical proteins.[27, 33] The morphology also affects the cellular uptake and 
biodistribution of MSNs.[34-36] Tang and co-workers studied the biodistibutions of 
rod-shaped MSNs with different aspect ratios. They found that short-rod MSNs are 
easily trapped in the liver, while long-rod MSNs accumulate in the spleen.[36] 
2.2.4 Pore size and structure 
Pore size is an important factor that affects adsorption and release of guest 
molecules in porous materials. For instance, it has been reported that increasing the 
pore diameter of SBA-15 type mesoporous silica from 8.2 to 11.4 nm resulted in the 
increase of bovine serum albumin loading from 15% to 27%.[37] In other reports, the 
decreases in pore diameter of MCM-41 or MCM-48 type mesoporous silica led to 
lower release rates of ibuprofen, erythromycin and other drugs.[38, 39] The commonly 
used pore template of cetyltrimethylammonium bromide (CTAB) can only produce 
pore dimensions in the range of 3–4 nm,[6] which could be further reduced after pore 
surface modification. Although the pore size of bulk mesoporous materials can be 
readily enlarged by using micelle swelling agent such as trimethylbenzene (TMB), 
pore size-expansion in nanoparticles is more challenging, as the dilute synthetic 
conditions often make the swelling agent preferentially dissolved in the solvent 
rather than in the surfactant micelles. Some researchers have tried to enlarge the 
pore size of CTAB templated MSNs by adding an excess amount of TMB as compared 
to CTAB,[40] or by hydrothermal treatment of the dried silica/surfactant composite in 
the presence of either TMB[41] or surfactants with longer alkyl chains.[42, 43] 
 Pore structure types, in terms of pore connectivity and geometry, also have an 
influence on the loading and release properties. To date, different geometrical 
arrangements (2D-hexagonal, 3D-hexagonal, and cubic,[44] as shown in Fig. 6) of pore 
arrays in MSNs have been obtained by the use of structure-directing agents that 
self-assemble with silica precursors.[45] It is reported that the interconnected pore 
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systems provide easier and faster diffusion process than unconnected pore 
systems.[46] 
 
Fig. 6 Pore geometry in mesoporous silica nanoparticles. 
2.3 Surface functionalization 
Surface functionalization is usually necessary for MSNs because it can endow the 
nanoparticles with desirable characteristics for delivery application such as improved 
biocompatibility, dispersibility, targeting specificity, and control of release. [47] 
Besides, the cellular uptake efficiency and uptake mechanism of the MSNs are also 
determined by the surface functional groups.[48-50] Till now, the MSNs have been 
functionalized with various reactive organic groups, such as amine, thiol, vinyl, azide, 
alkyne and maleimide, which means infinite possibilities for further 
modification.[51-55] 
 Depending on the morphology and structure, the MSNs have at least three 
distinct domains which can be independently functionalized: the particle framework, 
the external surface of nanoparticles and the surface in the mesopore channels. In 
general, there are two routes for surface functionalization of MSNs: co-condensation 
and post-grafting. 
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2.3.1 Co-condensation 
In co-condensation method, the functionalization is carried out during the 
nanoparticle synthesis. It involves co-condensation of hydrolyzed alkoxysilanes with 
organoalkoxysilanes in the presence of structure-directing agents and results in 
functionalized nanoparticles in one pot. Since the organic groups are direct 
components of the sliane precursor, they are generally more homogeneously 
distributed in the pore channels and pore blocking is not a problem. However, it is 
important to note that the organosilane present in the reaction media can disturb 
the assembly between the surfactant and the hydrolyzed silane, and lead to 
disordered mesostructure or reduction of pore size in the product. Therefore, the 
degree of functionalization by co-condensation is affected by the molecular size and 
the hydrophilic/hydrophobic nature of the organosilane.[51, 56] In addition, the SDA in 
the as-prepared product has to be removed by extraction, because calcination would 
remove the organic functional groups as well. Nevertheless, the co-condensation 
method can also be intentionally used to tune the morphology of MSNs.[57] For 
instance, a hydrophilic co-condensing agent leads to the formation of small and 
round particles while hydrophobic one gives rod shape particles.[56] More 
importantly, condensation reactions with bridged organosilica precursors of the type 
(R’O)3Si-R-Si(OR’)3 can produce the so-called periodic mesoporous organosilica (PMO) 
materials, which has organic units incorporated in the three-dimensional framework 
of the silica matrix.[13] 
2.3.2 Post-grafting 
In post-grafting method, the organic groups are introduced to the surfaces of 
mesostructured silica matrix after its formation. This process occurs typically by the 
reaction of free silanol groups on the silica surfaces with organosilanes such as 
(R’O)3SiR, although other reagents such as chlorosilanes, disilazanes, organolithium 
and Grignard reagents have also been reported.[58] The functionalization can be 
carried out either by solution-based reactions or by deposition from the vapor phase.  
In contrast to co-condensation, the mesostructure and morphology of MSNs can 
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usually be maintained using this functionalization. On the other side, because the 
silanols on the external particle surface and at the pore openings are more readily 
accessible than those inside the pores, post grafting can lead to a non-homogeneous 
distribution of the organic groups due to the limited diffusion of organosilanes. This 
preferential functionalization of external surface by post-grafting has been 
supported by X-ray photoelectron spectroscopy (XPS) results and affects the reaction 
and adsorption behavior of modified MSNs.[59, 60] The degree of inhomogeneity 
depends on both the reaction media/solvent and the type of grafting reagent. For 
example, in the case of grafting with 3-aminopropyltriethoxysilane (APTES), an 
anhydrous solvent like toluene is usually used because the silanes form clustering in 
the presence of water and lead to non-uniform distribution.[61] In addition, it was 
found that grafting silanes of larger size are more likely to be grafted onto external 
surface sites than smaller ones.[62] 
2.3.3 Site-selective functionalization 
Functional groups located at different parts of MSNs can affect the delivery 
performance in different aspects. The functional groups on the external particle 
surface can influence the biocompatibility, dispersibility and cellular uptake of MSNs, 
while the functional groups inside the mesopores can tune the loading and releasing 
of different drugs. Therefore, a site-selective functionalization for different domains 
of MSNs surface is highly desirable for delivery applications. Selective 
functionalization can be realized by making variations to the two basic 
aforementioned methods  
 A common method for selective functionalization is though post-grafting of 
organosilanes on mesoporous silica still containing the SDA. Because the pore 
channels of the as-prepared mesoporous silica are filled with SDA template, the 
functionalization should occur preferentially on the external surface due to the 
diffusion limit. Then, after extraction of the SDA, the inner surface can be 
functionalized separately. However, it should be noted that although this method 
are usually applicable for micrometer sized mesoporous silica, it is not always 
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successful for nanometer-sized MSNs. It has been reported that grafting reagents 
can still diffuse into the inner pores of MSNs even with the presence of SDA as a 
result of the reduced diffusion barrier of shorter channels.[62, 63] 
 Selective functionalization was also achieved by a sequential co-condensation 
approach.[64] In this method, different functionalized triethoxysilanes are added into 
the particle formation media at specific times of the particle growth. In this way, 
functional groups can be chosen to be completely dispersed inside the channels, 
concentrated in parts of the mesopores, or exclusively placed on the external surface 
as shown in Fig. 7. Furthermore, the functional group density can be adjusted by 
variation of the organosilane-to-silane ratio. 
 
Fig. 7 Site-selective functionalization by sequential co-condensation. Reproduced 
from Ref. [64] with permission. Copyright (2008) American Chemical Society. 
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2.4 Drug and gene delivery 
Since the first introduction of mesoporous silica materials to drug delivery in the 
early 2000s,[65] various types of mesoporous silica based delivery systems have been 
developed so far in order to achieve efficient drug loading, targeted drug delivery, 
controllable drug release and multi-functional theranostic purpose. Fig. 8 shows the 
structure of a typical MSNs-based multifunctional delivery platform. Some important 
achievements of MSN-based carrier over the last decade are summarized in this 
section. 
 
Fig. 8 MSNs as a platform for drug delivery. A) Nanoparticles attached to MSNs as 
functional gatekeepers. B) Hydrophobic/hydrophilic guest molecules entrapped in 
the interior of the nanochannels. C) Stimuli-responsive linkers, which chemically 
attach MSNs and gatekeepers. D) Grafting with a protecting polymer, such as PEG, 
shields the MSN surface from interacting with opsonizing proteins. E) Bioimaging 
agents such as magnetic nanoparticles, quantum dots, or fluorophores. F) Targeting 
ligands such as antibodies. G) Complexation with plasmid DNA. H) Additional ligands 
such as cell- penetrating peptides. I) Incorporation of a diagnostic label. J) 
Stimuli-responsive polymers. K) Attachment of functional groups that could modify 
the metabolism of cells. Reproduced from Ref. [3] with permission. Copyright (2010) 
John Wiley and Sons. 
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2.4.1 Drug loading 
One of the main advantages of MSNs in delivery application is their capability to 
carry various therapeutic reagents in large amounts due to their high specific surface 
areas and pore volumes. The loading cargo can be hydrophilic or hydrophobic in 
nature and their molecular weight can range from hundreds for small molecular 
drugs to hundreds of thousands for double-stranded DNA. The loading of 
therapeutics in MSNs can be can be generally divided into two categories according 
to the interaction mechanism: non-covalent and covalent. 
 Non-covalent loading is the most common method to construct a MSN-based 
delivery system. The cargos are absorbed on the outer surface or into the porous 
structure of MSNs through Van der Waals forces, hydrogen bonds, or electrostatic 
attraction. For hydrophilic drugs, the loading is commonly proceeded though 
adsorption from aqueous solution. In this case, the surface charge of MSNs need to 
be considered. The point of zero charge for primary silica, i.e. the pH at which the 
net-surface charge is zero, is about 2-3, due to the presence of surface silanol groups. 
Thus, primary MSNs are negatively charged under biologically relevant conditions 
and positively charged drugs such as doxorubicin can be readily absorbed. For 
negatively charged drugs, a surface modification of MSNs can be carried out to 
facilitate electrostatic attraction. For example, high amounts of salicylic acid have 
been absorbed by amine modified mesoporous silica while the primary material 
show negligible absorption.[66] Due to their structural integrity in organic solvents, 
the MSNs are especially suitable for loading hydrophobic drugs from nonaqueous 
media. For the loading process, the solvent can be chosen in a wide range according 
to the hydrophobic drug, which is usually difficult for organic or polymer carriers. 
 The other loading mechanism is covalently linking the drug to functional groups 
present on the MSNs. The unique advantage of covalent loading is that premature 
drug release can be effectively avoided. However, it is necessary to retain the drug 
activity after the chemical linkage is cleaved. Furthermore, this loading method is 
difficult for drugs without linkable groups in their molecular structure. 
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2.4.2 Targeted delivery 
To reduce unspecific toxicity and side effects, great efforts have been made to 
deliver drugs to the specific abnormal cells. The mesoporous silica based DDS are 
expected to achieve this goal through the following two methods: 
 1) Passive targeting. In chemotherapy of cancer, the passive targeting is based 
on tumor features including leaky blood vessels and poor lymphatic drainage. In 
contrast to free drugs which diffuse nonspecifically, a nano-sized drug carrier like 
MSNs can accumulate in the tumor tissues vessels by the enhanced permeability and 
retention (EPR) effect.[67] The passive targeting ability of MSNs is strongly related to 
their structural parameters including size and surface chemistry. It is reported that 
the nanoparticle sizes should be below 400 nm to escape from the leaky vasculature 
of tumors. Meanwhile, it is also necessary to prevent none-specific protein 
adsorption to the particles, which would cause rapid clearance of particles by the 
mononuclear phagocytic system.[68] This means providing MSNs with “stealth” 
properties need to be achieved by functionalizing the surface with biocompatible 
polymers, such as polyethylene glycol.[69] Although passive targeting can be achieved 
to a certain extent, there are limitations to this strategy. For example, some diseases 
such as blood cancer do not exhibit the EPR effect. Thus, other targeting methods 
should be developed. 
 
Fig. 9 Schematic illustration of targeted nanoparticles with peptide ligands. 
Reproduced from Ref. [70] with permission. Copyright (2013) Elsevier. 
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 2) Active targeting. The active targeting strategy is based on the fact that there is 
distinct differences between defect cells and normal ones. For example, it has been 
found that some receptors and antigens are over-expressed on the membrane of 
cancer cells, such as folate receptor, transferrin receptor, and human epidermal 
growth factor receptors. Therefore, the surface of MSNs can be modified with 
corresponding ligands that interact with these receptors of particular cells. These 
targeting ligands promote nanocarrier binding and cell internalization as illustrated 
in Fig. 9. The ligands can be antibodies,[71] aptamers,[72] peptides,[73] or small 
molecules.[48] It is worthy noting that the targeting objects are not limited to specific 
cells, but can also be sub-cellular organelles or particular tissue. For example, 
nuclear-targeting MSNs have been developed by conjugating MSNs with 
transactivator of transcription (TAT) peptide. The resulted carriers can facilitate the 
nuclear internalization of loaded anti-cancer drugs through the importin-mediated 
cytoplasm-nuclear transport and lead to a significant enhanced anticancer activity.[19] 
More recently, mitochondrial and tumor vascular targeting MSNs were also 
reported.[74, 75] 
2.4.3 Stimuli-responsive delivery 
 
Fig. 10 Schemes of MSNs as stimuli-responsive drug delivery devices. Reproduced 
from Ref. [69] with permission. Copyright (2013) The Royal Society of Chemistry. 
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As shown by Fig. 10, MSNs can be functionalized with various stimuli-responsive 
nanovalves or gateskeepers so that the drug release is precisely controlled via 
different internal and/or external stimuli, such as pH,[76] redox potential,[77] 
enzyme,[78],metal ion,[79] light,[80] and temperature.[81] 
 Responsive release based on pH variations has received the greatest attention 
because pH in the human body varies not only between different organs and tissues 
but also between normal and defected cells. For example, cancerous and 
inflammatory tissues (pH ≈  6.8), as well as endosomal and lysosomal cell 
compartments (pH ≈ 5.5), have a more acidic pH than blood or healthy tissues (pH 
≈ 7.4).[82] As shown in Fig. 11, cyclodextrin (CD) and Low-molecular-weight linear 
polyetherimide (PEI) complexes were utilized by Kim and co-workers to achieve 
controlled release in an acidic environment. Guest molecules were first loaded into 
pores and then CD/PEI inclusion complexes were attached onto the surface of MSNs. 
Due to the bulkiness of these compounds the cargo is protected until 
polypseudorotaxane is ruptured. Under acidic conditions, the CD complex can be 
broken and hence release of cargo.[83] 
 
Fig. 11 a) Synthetic route to PEI-functionalized silica particles. b) Schematic of 
pH-responsive release of guest molecules from mesoporous silica. i) succinic 
anhydride, triethylamine; ii) 1,1'-carbonyldiimidazole; iii) PEI. c) Schematic 
illustration of the pH dependence of polypseudorotaxane formation from PEI and 
CDs. Adapted from Ref. [83] with permission. Copyright (2007) John Wiley and Sons. 
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Fig. 12 Schematic representation of the CdS nanoparticle-capped MSN-based 
drug/neurotransmitter delivery system. Reproduced from Ref. [77] with permission. 
Copyright (2003) American Chemical Society. 
 The application of MSNs as redox-responsive DDS was demonstrated on the 
release of neurotransmitters by using CdS nanoparticles as the chemically removable 
caps (Fig. 12).[77] In this system, the CdS caps were conjugated to MSNs through the 
disulfide bond and the release of cargo was triggered by reducing agents such as 
dithiothreitol (DTT) and mercaptoethanol (ME). Because the intracellular glutathione 
(GSH) levels in most cancer cells are 100–1000-fold higher than the extracellular 
levels, the naturally occurring redox potentials between the extracellular and the 
intracellular space can be utilized as an internal stimulus to trigger the cargo release 
from MSNs.[84] Based on the same strategy, a series of redox-responsive MSN 
systems were developed by using different gatekeepers, such as Fe3O4
[85] and Au 
nanoparticles.[86] 
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Fig. 13 Enzymatic release of 5-aminosalicylic acid and sulfapyridine from MSNs in the 
presence of azoreductase. Reproduced from Ref. [78] with permission. Copyright 
(2012) John Wiley and Sons. 
 Enzyme responsive nanogating is a very interesting strategy due to the 
anomalous increase of enzymatic presence or activity in some specific tissues. In a 
proof-of-concept design as shown by Fig. 13, an azo-reductase-responsive delivery 
system was constructed by covalently bind sulfasalazine, a prodrug for inflammatory 
bowel disease, to MSNs. The drug was released only inside the colon through 
interaction with azo-reductase.[78] Other enzyme-responsive examples include 
biotin-avidin capped MSNs as a protease responsive system[87] and β-D-galactosidase 
responsive lactose coated MSNs.[88] In addition, Park et al. prepared alpha-amylase 
and lipase responsive MSNs using β-CD capping enzyme responsive system.[89] 
 Light responsive drug release also exhibits great potentials because it can be 
controlled both spatially and temporally. Fujiwara and co-workers reported the first 
light responsive mesoporous silica material for reversible photo-controlled 
release.[90] The pore walls of MCM-41 silica was grafted with coumarin, which goes 
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through reversible intermolecular dimerization under UV light. The dimerization of 
coumarin under UV light with wavelengths longer than 310 nm yields a cyclobutane 
product that blocks the mesopores. The exposure to 250 nm UV light cleaves the 
cyclobutane ring of the coumarin dimer and lead to cargo release. Zink et al. 
employed photoisomerization of azobenzene to expel luminescent molecules from 
the nanopores of MSNs by tethering azobenzene molecules to the interior walls of 
the mesopores.[80] As illustrated by Fig. 14, the azobenzene molecules are exited at 
wavelength around their isosbestic point (400–450 nm). Both the trans-to-cis and 
cis-to-trans isomerization can be activated, driving the wagging motions of 
untethered portion of azobenzene molecules. This sweeping motion physically 
expels the cargo from the confined nanopores of the nanoparticles, thereby acting as 
sort of a nanoimpeller. 
 Temperature is another stimulus that can be used to trigger the delivery from 
MSNs. The conjugation of various thermo-sensitive polymers, such as 
poly(N-isopropylacrylamide) (PNIPAM) and its derivatives, onto the surface of MSNs 
have been used for the construction of a thermo-responsive release system.[91] 
These temperature-sensitive polymers are able to swell or shrink in response to 
temperature changes, which lead to the open or close of the nanogates. 
 
Fig. 14 photo-responsive azobenzene-functionalized silica particles. Reproduced 
from Ref. [80] with permission. Copyright (2007) American Chemical Society. 
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2.4.4 Gene delivery 
Gene therapy holds promise for the treatment of both acquired and inherited 
diseases like Alzheimer’s disease, cancer, cardiovascular, inflammatory, adenosine 
deaminase deficiency, and cystic fibrosis. In gene therapy, foreign nucleic acids are 
delivered into living cells where they can alter gene expression at the transcriptional 
or post-transcriptional level. Many forms of nucleic acids exist as current and 
potential therapeutics, such as plasmids, antisense oligonucleotides, ribozymes, 
DNAzymes, aptamers, and small interfering RNA (siRNA). However, these nucleic 
acids are large, negatively charged molecules that cannot cross a negatively charged 
plasma membrane by passive diffusion. Furthermore, they are highly susceptible to 
enzymatic degradation by serum nuclease. Therefore, the successful gene therapy 
strongly relies on efficient delivery vehicles.[92, 93] Current gene delivery systems are 
divided into two major categories: viral and non-viral. Although viral carriers 
generally exhibit higher efficiency than non-viral ones, they also raise potential risk 
such as excessive immune response and mutagenesis. On the other hand, non-viral 
systems have drawn great research interest in recent years due to the ease of 
preparation and reduced safety concern.[94, 95] 
Among various non-viral carriers, silica-based nanocomposites have unique 
advantages such as well-defined morphology, size, versatile surface functionalization 
and good biocompatibility.[96-98] Previous researches on silica-based gene delivery 
carrier fall into two general aspects: surface chemistry and particle structure. For 
surface chemistry, because the primary silica surface is negatively charged under 
biologically relevant conditions, the loading of nucleic acids are usually carried out 
on silica surface modified by various species such as metal ions,[99] amine silane,[95] 
cationic polymers,[100, 101] and peptides.[102] For particle structure, the silica based 
gene carriers have evolved from solid spheres to mesoporous nanoparticles, and 
hierarchical structure like hollow or dendric particles.[41, 100, 103-107] It has been proven 
that porous silica with large mesopore sizes (>10 nm) are more favourable for 
loading nucleic acids than those with small pores (<5 nm).[41, 99, 104, 105, 107] 
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2.4.5 Co-delivery of multiple cargos 
For the treatment of many diseases (in particular cancer, cardiovascular diseases, 
neurological disorders, malaria, and acquired immune deficiency syndrome), it is 
desirable to deliver a combination of different drugs to maximize therapeutic effect 
and reduce drug resistance.[108] The structure and surface chemistry of MSNs can be 
optimized for co-delivery of various new drugs with diverse physicochemical 
properties.  
 For diabetic treatment, Lin and co-workers developed boronic 
acid-functionalized MSNs for controlled release of both insulin and cyclic adenosine 
monophosphate (cAMP). Gluconic acid-modified insulin proteins (G-Ins) were 
immobilized on the exterior surface of MSN through glucose-responsive boronic 
ester bond and also served as caps to encapsulate cAMP molecules inside the 
mesopores of MSNs. The introduction of saccharides triggered the release of both 
G-Ins and cAMP. The system is superior than the conventional glucose-responsive 
insulin delivery systems in that the decrease of insulin release with cycles can be 
balanced by the release of cAMP from the mesopores.[109]  
 Co-delivery by MSNs has also been explored for cancer therapy. He and 
co-workers encapsulated an anticancer drug doxorubicin (Dox) inside the mesopores 
of MSNs and modified the MSNs with polyamidoamine (PAMAM) dendrimers. The 
dendrimers further complexed with siRNAs targeted against mRNA encoding Bcl-2 
protein, which is the main player for nonpump resistance. The anticancer efficacy of 
Dox co-delivered with siRNA increased 132 times compared to free Dox, mainly 
because the simultaneously delivered siRNA significantly suppressed the Bcl-2 mRNA, 
and efficiently overcome the nonpump resistance.[110] 
2.4.6 Multi-functional delivery system 
Instead of just being a drug/gene carrier, mesoporous silica nanoparticles can be 
combined with other functional species to form multi-functional nanocomposites for 
diagnosis and therapy purpose. For example, mesoporous silica nanocomposites 
with magnetic and/or luminescent components represent the most widely reported 
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multifunctional theranostic agents. Luminescent materials (such as organic dyes, 
quantum dots, and rare-earth nanophosphors) or magnetic nanoparticles have been 
successfully combined with the mesoporous silica in the form of covalent linkage, 
core–shell, embedded or rattle-type structures as shown in Fig. 15.[111] These 
strategies to fuse luminescence and magnetism into one mesoporous silica matrix 
enable a multifunctional carrier by which therapeutic and diagnostic capabilities are 
achieved at the same time. 
 
Fig. 15 Magnetic nanoparticle/ mesoporous silica nanocomposites: A) mesoporous 
silica spheres embedding monodisperese magnetic nanocrystals, B) microspheres 
encapsulating magnetic cores into perpendicularly aligned mesoporous shells, C) 
ordered mesoporous materials loaded with magnetic nanoparticles inside the 
porous channels or cages, and D) rattle-type magnetic nanocomposites. Reproduced 
from Ref. [112] with permission. Copyright (2011) John Wiley and Sons. 
2.4.7 Biocompatibility 
A critical issue for any drug delivery system is its biocompatibility. Silica is viewed as 
low toxicity and has been classified as a generally recognized as safe material (GRAS) 
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by the U.S. Food and Drug Administration (FDA).[113] However, the potential toxicity 
and hazardous effects of nanosized MSNs still need more detailed investigation, 
especially the long term fate in vivo. Several reports have proven the degradation of 
mesoporous silica materials in vitro.[114] Furthermore, the excretion of silica species 
via urinary and hepatobiliary system has been observed in vivo after intravenous 
injection.[17, 36] However, due to the varied structure of mesoporous silica materials 
and the different synthesis processes, there is still no consensus in the toxicity of 
MSNs.[11] The toxicity of MSNs can be influenced by various factors including particle 
size,[115] surface modification,[114] porous structure,[14] dosage,[116] cell types,[117] 
injection methods[118] etc.. A viewpoint is that toxicity is related partly to surface 
silanol groups,[119] which can interact with membrane components by hydrogen 
bond or with the positively charged tetraalkylammonium-containing phospholipids 
by electrostatic force. 
2.5 Summary 
Mesoporous silica nanoparticles have risen as a potential multifunctional drug/gene 
delivery platform to enhance therapeutic efficacy and reduce side effects. However, 
as a new application in nanomedicine, the MSN-based delivery systems still face two 
major challenges at the present stage: 
 1) Loading and delivery of large biomolecules. With the fast development of 
biomedicine, proteins (enzymes, antibodies) and genes (DNA, RNA) have emerged as 
new therapeutic agents and required effective delivery vehicle.[120, 121] These 
biomolecules are much larger in size than common small molecule drugs. However, 
in most previously reported MSNs, the pore sizes are usually too small (< 5 nm) to 
encapsulate large biomolecules. Meanwhile, most of the studied MSNs for delivery 
application are of the MCM41-type with hexagonal pore array, which lacks structure 
flexibility to simultaneously accommodate multiple different cargos. Thus, the 
particle and pore structure of MSNs need to be further optimized for loading and 
delivery of large therapeutic agents. 
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 2) Targeted delivery and controlled release. Although intensive research efforts 
have been made to achieve targeted delivery and controlled release by surface 
functionalization of MSNs, the reported functionalization strategies often suffer form 
different drawbacks. A prominent issue is the cost of functionalization over the 
benefits.[122] Many functionalization methods involve the usage of expensive 
biomolecules and complex synthesis procedure, which not only increase the 
fabrication cost of the whole delivery system but also bring in additional 
toxicity/biocompatibility concern and regulatory hurdles. Besides, in many earlier 
designs, the controlled release usually lies at a conceptual level. For instance, some 
stimuli-responsive systems have gating features in non-aqueous solvents, or employ 
external stimuli such as UV light that is not suitable for physiological environment.[88] 
Therefore, the surface functionalization of MSNs still need to be explored to achieve 
targeted delivery and controlled release in an economic, safe and realistic way. 
 To meet the above the above challenges, the researches in this thesis have been 
focused on the following two aspects: 
 1) Novel silica nanostructure for gene delivery. In chapter 3, we systematically 
investigated the synthesis of stellate mesoporous silica nanoparticles, which have 
radial pore sizes up to 20 nm. In chapter 5, we further incorporated this radial pore 
structure into magnetic core-shell nanoparticles and applied them for siRNA delivery. 
In chapter 6, we developed bowl-like mesoporous organosilica nanoparticles with 
large central cavities for DNA delivery. 
 2) Simple and effective silica functionalization for delivery purpose. In chapter 3, 
we functionalized the silica nanoparticles with low molecular weight 
poly(ethyleneimine) and studied its effect on drug delivery. In chapter 4, we 
fabricated a cancer-cell-specific nuclear-targeted nanocarrier by modifying the silica 
nanoparticles simultaneously with two targeting ligands, folic acid and 
dexamethasone, both of which are FDA approved molecules. In chapter 5, we 
developed a pH-responsive capping for magnetic silica nanoparticles. The capping 
was prepared by a facile one-pot coating of tannic acid, which is a natural polymer 
and generally recognized as safe by FDA. 
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Chapter 3 Tunable Stellate Mesoporous Silica 
Nanoparticles for Intracellular Drug Delivery 
3.1 Introduction, Significance and Commentary 
Mesoporous silica nanoparticles have attracted great research interests for their 
potential as drug delivery carriers. To achieve highly efficient delivery, the 
nanoparticle properties such as size, morphology, pore structure and surface 
functionalization need to be tightly controlled. In this work, we first demonstrated 
the controllable synthesis of uniform mesoporous silica nanoparticles with special 
stellate pore structure. Then, surface functionalization of these particles was carried 
out to construct a label-free anticancer drug carrier with enhanced intracellular 
delivery capability. The highlights and novelty of this work include: 
1. Controllable synthesis with clarified mechanism.  
 Systematic study was conducted to elucidate the effects of synthesis conditions 
(including reaction temperature and time, and reagent ratio) on the structure of 
stellate mesoporous silica nanoparticles. The particle size of these nanoparticles can 
be tailored continuously ranging from 50 to 140 nm and the pore size from 2 to 20 
nm. Based on experimental results, a consistent two-phase reaction mechanism is 
proposed for the particle formation process. 
2. Label-free drug carrier with enhanced intracellular delivery capability. 
 After modification of the stellate mesoporous silica nanoparticles with low 
molecular weight polyethyleneimine though a glutaraldehyde linker, the resulting 
nanocomposites not only possess auto-fluorescence allowing for convenient particle 
tracking, but also show enhanced intracellular delivery efficacy compared with both 
unmodified and amine modified counterparts when used as an anticancer drug 
carrier. 
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3.2 Tunable Stellate Mesoporous Silica Nanoparticles for 
Intracellular Drug Delivery 
This section is included in the thesis as it appears as a paper published by L. Xiong, X. 
Du, B. Shi, J. Bi, F. Kleitz and S. Z. Qiao. Tunable stellate mesoporous silica 
nanoparticles for intracellular drug delivery, J. Mater. Chem. B, 2015, 3, 1712. 
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3.3 Supplementary Information 
This section is included in the thesis as supplementary information to section 3.2. It 
includes additional information which is not put in the main text of the published 
paper, but as electronic supplementary information freely accessible online. 
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Fig. S1 Surface functionalization reactions of mesoporous silica nanoparticles. 
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Fig. S3 TGA (a) and DTG (b) curves of as-prepared samples synthesized with mixed 
surfactants. 
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Fig. S4 Nitrogen adsorption-desorption isotherms (a) and respective pore size 
distribution curves (b) of stellate particles after various reaction times (6 h, 12 h, 18 h 
and 24 h) at 35 °C. 
 
 
Fig. S5 TEM images (a), nitrogen adsorption-desorption isotherms (b) and 
respective BJH pore size distribution curves (c) of T50 and T50-24h.
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Fig. S6 SEM images of particles synthesized under various catalyst concentrations: 
(A) TC/2, (B) TC/4, (C) TC/8 and (D) TN. 
 
 
Fig. S7 Nitrogen adsorption-desorption isotherms (a) and respective pore size 
distribution curves (b) of particles synthesized under different TEA/TEOS ratio. 
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Fig. S8 Color changes of silica nanoparticles from white to yellow and brown after 
glutaraldehyde and PEI conjugation. 
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Fig. S11 CLSM images of Hela cells after incubation with 50 µg/ml DOX loaded 
PEI-MSN for 8 h. Image (D) is the merge picture of blue channel from Hoechst (A), 
green channel from PEI-silica (B), red channel from DOX (C) and the differential 
interference contrast (DIC) channel. Scale bars are 50 µm. 
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Fig. S12 CLSM images of Hela cells after incubation with DOX loaded PEI-MSN for 
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Chapter 4 Cancer-Cell-Specific Nuclear Targeted Drug 
Delivery by Dual Ligand Modified Mesoporous Silica 
Nanoparticles 
4.1 Introduction, Significance and Commentary 
Nuclear-targeted anticancer drug delivery by mesoporous silica nanoparticles has 
emerged as a novel strategy for enhancing anti-cancer efficacy and overcoming drug 
resistance. However, almost all the previous nuclear-targeted mesoporous silica 
nanocarriers were using Trans-Activator of Transcription (TAT) peptide as the 
nuclear-targeting ligand, which could lead to unselective cellular uptake by healthy 
cells and severe side toxicity. Although several improved designs were proposed for 
TAT modified MSNs recently, they still had several disadvantages such as complex 
fabrication process and lack of versatility as cancer cell-specific nuclear-targeted 
delivery systems. 
 In this work, in order to circumvent the inherent limitation of TAT modified 
MSNs, a novel and simple dual-ligands strategy is developed for MSNs towards 
cancer cell-specific nuclear-targeted drug delivery. The dual-ligands modified MSNs 
are not only able to induce higher inhibition efficacy on cancer cells through active 
nucleus accumulation, but also reduce toxic side effects on non-cancer cells though 
receptor-mediated selective cellular uptake. The highlights and novelty of this work 
include: 
1. Dexamethasone as the nuclear targeting ligand.  
 Dexamethasone was covalently conjugated to MSNs (~40 nm in size) for the first 
time by a mild reaction. The nuclear targeting function of dexamethasone was 
verified on MSNs and resulted in significantly enhanced cancer cell inhibition when 
the anticancer drug doxorubicin was loaded. 
2. Cancer cell and nuclear dual-targeting on one carrier. 
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 By combing co-condensation and post-grafting, both a cell targeting ligand (folic 
acid) and a nuclear targeting ligand (dexamethasone) were conjugated to the same 
MSN carrier. The two targeting ligands can work collaboratively without interference, 
and a cell-nucleus sequential targeting can be achieved with the dual-modified 
MSNs. 
4.2 Cancer-Cell-Specific Nuclear-Targeted Drug Delivery by 
Dual-Ligand-Modified Mesoporous Silica Nanoparticles 
This section is included in the thesis as it appears as a paper published by L. Xiong, X. 
Du, F. Kleitz and S. Z. Qiao. Cancer-Cell-Specific Nuclear-Targeted Drug Delivery by 
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4.3 Supplementary Information 
This section is included in the thesis as supplementary information to section 4.2. It 
includes additional information which is not put in the main text of the published 
paper, but as electronic supplementary information freely accessible online. 
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Tetraethyl orthosilicate (TEOS), γ -mercapto-propyl trimethoxysilane (MPTES), 
(3-Aminopropyl)-triethoxysilane (APTES), triethanolamine, triethylamine, cetyl 
trimethylammonium bromide (CTAB), folic acid (FA), toluene, ethanol, 
dimethylsulfoxide (DMSO), N-ethyl-N’(3-dimethylaminopropyl)carbodiimide  
hydrochloride  (EDC), fluorescein isothiocyanate (FITC), 
3-[4,5-dimethylthialzol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), trypsin (0.25%) 
were purchased from Sigma Aldrich. Dexamethasone-21-mesylate was purchased 
from Steraloids Inc. (Newport, RI). Doxorubicin hydrochloride (DOX) was purchased 
from Bejing Huafeng United Technology Co., Ltd. Dulbecco's Modified Eagle's 
Medium (DMEM), fetal bovine serum (FBS), and phosphate buffered saline (PBS) 
were purchased from Gibco-BRL (Grand Island, USA). All chemicals were used as 
received without further purification. Water used in all experiments was purified 
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using a Milli-Q Plus 185 water purification system (Millipore, Bedford, MA) with a 
resistivity higher than 18 MΩ cm. 
Synthesis and functionalization of MSNs 
The procedure for nanoparticle synthesis and functionalization is presented in 
Scheme 1 and Scheme S1. At first, unmodified plain MSNs (pMSN) and thiol-modified 
MSNs (MSN-SH) were synthesized separately according to a slightly modified 
reported method.[1] For pMSN, 3 mL of TEOS was added quickly into 25 ml of 
aqueous solution containing 0.4 g of CTAB under vigorous stirring and 87 mg of 
triethanolamine. The mixture was allowed to react for 2 h at 80 °C followed by 
centrifugation at 16000 rpm for 10 min to precipitate the nanoparticles. For MSN-SH, 
the procedure was almost the same as above except that a 200 µL mixture of TEOS 
and MPTES (volume ratio 1:1) was added 1 h after the reaction began. The CTAB 
containing-precipitate was washed with DI water three times and dried in vacuum 
oven for further treatment. For FITC labelling, 10 mg of FITC was mixed with 50 µL of 
APTES in 5 ml of ethanol for 24 h under dark condition to form a stock FITC-APTES 
solution. The synthesis procedure of FITC-labelled MSNs was almost the same as the 
unlabelled counterparts except that 100 µL of FITC-APTES stock solution was added 
with TEOS during the reaction. 
Next, pMSN or MSN-SH was conjugated to folic acid (FA) to obtain FA-MSN or 
FA-MSN-SH by a post-grafting method.[2] Briefly, 44 mg of folic acid was dissolved in 
5 mL of anhydrous DMSO containing 100 mg of EDC and stirred for 2 h under dark 
environment. Then 30 µL of APTES was added to the activated FA solution and 
stirred for another 4 h. After that, the mixture was added directly to 20 mL of 
toluene containing 500 mg of pMSN or MSN-SH obtained in the previous step. The 
mixture was allowed to react at 80 °C for 24 h followed by centrifugation. The 
precipitate was washed by toluene and ethanol sequentially. The CTAB in the 
product was removed at this time by extraction in 100 ml 2 wt % NH4NO3/ethanol 
solution for two times. 
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Finally, folic acid and dexamethasone dual modified MSNs (FA-MSN-DEX) were 
prepared through a highly selective reaction between α-Keto mesylates and thiol 
groups.[3] Briefly, 10 mg of dexamethasone methylate and 20 mg of 
surfactant-extracted FA-MSN-SH was dispersed in 10 mL anhydrous DMSO. Then 5 
µL of triethylamine was added and the mixture was stirred at room temperature for 
6 h followed by centrifugation. The precipitate was washed sequentially with DMSO 
and DI water for several times and dried in vacuum oven for further use. 
DOX loading and release 
For DOX loading, 5 mg of MSN, FA-MSN or FA-MSN-DEX were mixed with 5 ml of 
DOX solution in PBS (0.5 mg mL-1) and stirred for 24 h under dark environment. Then, 
the nanoparticles were collected by centrifugation at 16000 rpm for 10 min. The 
precipitate was washed gently with PBS for three times and dried at 60 °C. To 
evaluate the DOX loading efficiency, the supernatant and all the washing liquid 
fractions were collected, and the residual DOX content was determined using a 
standard curve by UV-vis adsorption at 480 nm. The release profile of DOX from 
MSNs was investigated at 37 °C in two different release media: (a) acetate buffer, pH 
5.0; and (b) PBS, pH 7.4, using a dialysis bag diffusion technique. The DOX-loaded 
particles (5 mg) were suspended in 5 mL release media in the dialysis membrane bag 
(MWCO ¼  16K) and the bag was immersed in 15 mL release media and shaken at a 
speed of 100 rpm at 37 °C. The amount of DOX released at different time intervals 
was determined by UV-vis measurement at 480 nm. 
Cell culture and cell viability 
HeLa or HEK293 cells were grown in DMEM culture medium supplemented with 10% 
(v/v) FBS in a humidified 5% CO2 atmosphere at 37 °C. For all experiments, cells were 
harvested by using 0.25% trypsin and resuspended in fresh medium before plating. 
The viability of cells in the presence of MSNs was investigated using MTT assay. HeLa 
or HEK293 cells were seeded into 96-well plates at a density of 1 × 104 per well in 
100 μL of media and grown for 24 h. Then, the growth medium was replaced with 
100 μL of cell culture medium containing different concentrations of nanoparticles 
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with or without DOX loading. After incubation for 24 h, the medium was removed. 
Then 100 μL fresh medium and 10 μL MTT (5.0 mg mL-1 in PBS) were added to each 
well and the cells were further incubated for 4 h. After that, the growth medium was 
removed and 150 μL of DMSO was added to each well to ensure complete 
solubilisation of formazan crystals. Finally, the absorbance was determined using a 
micro-plate reader (Biotek, USA) at the wavelength of 570 nm. The viability of 
untreated cells was assumed to be 100%. 
Cellular uptake by confocal laser scanning microscopy (CLSM) 
To check cellular uptake and subcellular localization of MSNs, HeLa cells were seeded 
at a concentration of 2×105 cells/well in a 6-well plate with one piece of cover glass 
at the bottom of each well and cultured for 24 h. FITC-labelled MSNs were then 
added to the incubation medium at a concentration of 50 μg mL-1. After 24 h, the 
medium was removed. The cells were washed twice with PBS and fixed with 4 wt % 
formaldehyde. The cell nucleus was stained with Hoechst 33258 (1 μg mL-1) for 15 
min at room temperature. After the staining, the cells were softly washed again with 
PBS to remove excessive Hoechst dye. At last, 2 mL of PBS was added and the cover 
glass was visualized under a confocal laser scanning microscope (Leica Confocal 
1P/FCS). Optical sections were averaged 4 times to reduce noise. Images were 
processed using Leica confocal software. 
Cellular uptake by flow cytometry 
HeLa or HEK293 cells were seeded at 1×105 in 12 well plates. After 24 h attachment, 
the cells were treated with FITC-labelled pMSN, FA-MSN or FA-MSN-DEX dispersed in 
culture medium (50 μg mL-1) for 24 h. Then, the cells were washed with PBS twice to 
remove the extracellular particles and trypsinized. After centrifugation and washing 
with PBS, the cells were resuspended in PBS containing trypan blue (200 μg mL-1). 
The fluorescence of endocytosed particles was detected by a FACSCalibur flow 
cytometer (Becton Dickinson) in FITC-A channel. The cellular uptake was calculated 
by the percentage of fluorescence positive cells using the untreated cells as negative 
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control. 2×104 cells were analysed at a rate of 200-600 cells per second. CellQuest 
software was used for data analysis. 
Cell and nuclear uptake by ICP-MS 
Hela cells were seeded at 1×106 cells in T25 flasks. After 24 h attachment, the cells 
were treated with pMSN, FA-MSN or FA-MSN-DEX dispersed in culture medium (50 
μg mL-1) for 24 h. Then, the cells were washed with PBS twice and trypsinized. After 
centrifugation, the cell pellet was washed twice with PBS. The cell nuclei were 
separated from the cell cytosol following a reported procedure.[4] The cells were 
suspended in a nuclei extraction buffer (100 mM NaCl solution with 1 mM EDTA, 1% 
Triton X-100, and 10 mM Tris buffer) at a concentration of 106 cells mL-1 for 10 min 
at 4 °C. The suspension was then centrifuged and the cell nuclei were collected as 
the resulting precipitate. Then 3 mL cell lysis solution (0.5% Triton X-100, 1 M NaOH) 
was added to disrupt the cell nuclei with ultrasound. The mass of pMSN, FA-MSN or 
FA-MSN-DEX in the nuclei was determined by measuring the silicon concentration 
with inductively coupled plasma mass spectrometry (ICP-MS). The cellular uptake of 
pMSN, FA-MSN or FA-MSN-DEX was quantified as described above without the step 
of nuclei separation. 
Characterization 
Scanning electron microscopy (SEM) observation was carried out on a FEI Quanta 
450 FEG environmental emission scanning electron microscope with energy 
dispersive X-ray (EDX) accessory. Specimens were coated with platinum before SEM 
observation. For transmission electron microscopy (TEM) observation, the powder 
samples were dispersed in ethanol by sonication for 20 min, and deposited onto 
carbon-coated copper grids. TEM observation was carried out on a FEI Tecnai G2 
Spirit transmission electron microscope at an acceleration voltage of 120 kV. UV-vis 
absorption spectra were recorded on a UV-2600 spectrophotometer (Shimadzu 
Corporation). Fourier transform infrared (FTIR) spectra were recorded on a Thermo 
Scientific NICOLET 6700 FTIR spectrometer at room temperature. Thermogravimetric 
analysis (TGA) was performed on a S60/51920 TGA/DSC thermogravimetric analyzer 
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(Setaram Instrumentation), using an oxidant atmosphere (oxygen, 30 mL min-1) with 
a heating ramp of 10 ˚C min-1. Nitrogen adsorption-desorption measurement was 
carried out at -196 ˚C using a TriStar II surface area and porosity analyzer from 
Micromeritics. Prior to the measurement, the samples were degassed at 120 ˚C for 
12 h. Brunauer-Emmett-Teller (BET) specific surface area was calculated using 
adsorption data at a relative pressure range of P/P0 range of 0.05-0.30. Pore size 
distribution was derived from adsorption branch of the isotherm using the 
Barrett-Joyner-Halenda (BJH) method. Pore volume was determined from the 
amount of N2 adsorbed at the single point of P/P0=0.99. The hydrodynamic size and 
zeta-potential of nanoparticles in aqueous dispersions were measured on a Malvern 
Zetasizer Nano ZS (Malvern Inst. Ltd., U.K.) operating at a wavelength of 633 nm, 
where scattered light was collected at a fixed angle of 173°. Concentrations of silicon 
were determined with an Agilent 7500cs ICP-MS using a standard curve. Solid state 
13C cross-polarization magic-angle spinning nuclear magnetic resonance (13C CP/MAS 
NMR) measurement was performed on a Bruker Avance III 400 MHz spectrometer 
equipped with a 4 mm solid state probe. 
Statistical analysis 
Quantitative data were reported as mean ± standard deviation (SD) of at least three 
independent experiments. The statistical analyses were performed using a two 
sample, two tailed Student's t-test, with a p-value less than 0.05 considered being 
statistically significant. 
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Supplementary Figures and Calculation 
 





Figure S1. Hydrodynamic particle size distributions in water (a), digital photos and 
Tyndall effects (b) of (A, D) pMSN, (B, E) FA-MSN-SH, (C, F) FA-MSN-DEX in water, 
hydrodynamic particle size distributions in DMEM supplemented with 10% FBS (c). 
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Figure S3. SEM (left) and Energy-dispersive X-ray spectrum (right) of MSN-SH. 
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Figure S4. Solid state 13C CP/NMR of MSN-DEX obtained by reaction of MSN-SH with 
dexamethasone methylate. Note: for the clarity of spectrum interpretation, this 
sample is prepared without the folic acid modification step. The peaks around 60 
ppm denoted with * are assigned to the carbon atoms of residue ethoxy groups, 
which originated from incomplete silane hydrolysis and/or the ethanol extraction 
process.[5-6] 
 
 80  
 
Figure S5. Viability of Hela (a) and HEK293 (b) cells after 48 h of incubation with 




Figure S6. Low magnification CLSM images of Hela cells after 24 h of incubation with 
50 µg ml-1 FITC-labelled mesoporous silica nanoparticles. 
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Figure S7. Flow cytometry analysis of the uptake of FITC-labelled (a) MSNs with 
HEK293 cells and (b) MSN-SH before and after DEX conjugation by Hela cells after 24 
h of incubation. The histograms show distribution of events on the green (FL1) 
channel. MFI: mean fluorescent intensity. 
 
Figure S8. CLSM images of Hela cells after 24 h of incubation with 50 µg ml-1 
FITC-labelled MSN-SH (only thiol modified) and MSN-DEX (only DEX modified). Note 
that although MSN-DEX can be observed in some nuclear region, the overall cellular 
uptakes for both MSN-SH and MSN-DEX are very limited. 
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Figure S9. Z-stack images of one Hela cell after 24 h of incubation with 50 µg ml-1 
FITC labelled FA-MSN-DEX. 
 


































Figure S10. Standard calibration curve of silicon concentration measured by ICP-MS. 
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Figure S11. Standard calibration curve of DOX in aqueous solution. 
 


































time (h)  
Figure S12. DOX release profiles from mesoporous silica nanoparticles under 
different pH values. 
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Figure S13. Low magnification CLSM images of Hela cells after 12 h of incubation 
with DOX-loaded mesoporous silica nanoparticles. The equivalent DOX 
concentration in all the three samples was 5 µg ml-1. 
 
 
Quantification of grafted functional groups 
The weight loss of pMSN, MSN-SH, FA-MSN-SH and FA-MSN-DEX are 6%, 10%, 16% 
and 26% from TGA, respectively. Assuming the solid residue after calcination at 800 
˚C is pure silica, the burned-off contents (including organic functional groups and 
dehydrated hydroxyl groups) per gram of SiO2 are 64 mg, 110 mg, 190 mg and 350 
mg for the four samples. Because the functionalization was carried out step by step, 
the grafted quantity can be estimated from the differences between the burned-off 
contents.  
The difference between pMSN and MSN-SH is due to mercapto-propyl group 
(-CH2CH2CH2SH, 75 g mol
-1), thus the thiol group quantity per gram of SiO2 can be 
determined as  
(110 mg -64 mg)/ 75 g mol-1= 0.61 mmol g-1; 
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The difference between MSN-SH and FA-MSN-SH is due to FA-APTES conjugate, 
(C19H18N7O5-NHCH2CH2, 481 g mol
-1), thus the FA quantity per gram of SiO2 can be 
determined as 
(190 mg -110 mg)/ 481 g mol-1= 0.17 mmol g-1; 
The difference between FA-MSN-DEX and FA-MSN-SH is due to DEX (C22H28FO4, 375 g 
mol-1), thus the DEX quantity per gram of SiO2 can be determined as 
(350 mg -190 mg)/ 375 g mol-1= 0.43 mmol g-1. 
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Chapter 5 Magnetic Core-Shell Silica Nanoparticles with 
Large Radial Mesopores for siRNA Delivery 
5.1 Introduction, Significance and Commentary 
Gene therapy through small interfering RNA (siRNA) is a promising technology to 
treat cancer and other diseases. The successful RNA interference therapy strongly 
relies on the development of efficient gene delivery systems. In this contribution, a 
novel type of magnetic core–shell mesoporous silica nanoparticles was developed 
for siRNA delivery. The capability of this nano-carrier to load, protect and deliver 
anti-cancer siRNA into the cancer cells was demonstrated in vitro. The highlights and 
novelty of this work include: 
1. Magnetic core-shell silica nanoparticles with large radial mesopores  
 A novel type of super-paramagnetic core-shell mesoporous silica nanoparticles 
with large radial mesopores was fabricated for the first time. These nanoparticles 
exhibit small particle size of 150 nm, large open mesopores of 12 nm, large surface 
area of 411 m2 g-1, high pore volume of 1.13 cm3 g-1 and magnetization of 25 emu g−1 
simultaneously. The small particle size, high siRNA loading capability and strong 
response under external magnetic fields make these nanoparticles a very suitable 
carrier for intracellular delivery of siRNA. 
2. Tannic acid/Al3+ coating serves as an acid-liable pore capping 
 Acid-liable Tannic acid/Al3+ complex was formed as a coating layer onto the 
siRNA-loaded magnetic core-shell mesoporous silica nanoparticles to cap the radial 
mesopores. The tannic acid/Al3+ layer can further protect siRNA against enzyme 
degradation under neutral extracellular condition and decompose in the mild acidic 
intracellular environment for on-demand release of siRNA. 
3. Magnetic field enhanced delivery 
 The cellular uptake of the siRNA-loaded nano-carrier was compared both with 
and without the presence of an external magnetic field. Under the external magnetic 
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field, the cellular uptake was significantly increased (up to 40% in 6 h) which led to 
enhanced inhibition efficacy on human osteosarcoma cancer cell line. 
5.2 Magnetic Core-Shell Silica Nanoparticles with Large Radial 
Mesopores for siRNA Delivery 
This section is included in the thesis as it appears as a paper published by L. Xiong, J. 
Bi, Y. Tang and S. Z. Qiao. Magnetic Core-Shell Silica Nanoparticles with Large Radial 
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5.3 Supplementary Information 
This section is included in the thesis as supplementary information to section 5.2. It 
includes additional information which is not put in the main text of the published 
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I. Experiment Section 
Materials 
Tetraethyl orthosilicate (TEOS), (3-Aminopropyl)-triethoxysilane (APTES), 
triethanolamine (TEA), cetyltrimethylammonium bromide (CTAB), Iron(III) chloride 
hexahydrate (FeCl3·6H2O), ethylene glycol (EG), sodium acetate anhydrous (NaAc), 
tannic acid (TA), aluminium(III) chloride, 3-(N-morpholino)propanesulfonic acid 
(MOPS), hexane, ethanol, methylsulfoxide (DMSO), 2-(N-morpholino)ethanesulfonic 
acid (MES), ammonium nitrate, sodium dodecyl sulfate (SDS), poly(acrylic acid) (PAA, 
M.W.=800), 3-[4,5-dimethylthialzol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), 
KHOS (human osteogenic sarcoma) cell lines, siRNA targeting polo-like-kinase 1 
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(siPLK1), siRNA targeting enhanced green fluorescent protein (siEGFP), and 
ribonuclease A from bovine pancreas (RNase) were purchased from Sigma Aldrich. 
Fluorescein isothiocyanate (FITC)-conjugated siRNA was purchased from Santa Cruz 
Biotechnology. Ethylenediaminetetraacetic acid disodium salt (EDTA-2Na) was 
purchased from Ajax Finechem, Australia. Dulbecco's Modified Eagle's Medium 
(DMEM), fetal bovine serum (FBS), and phosphate buffered saline (PBS), Tris 
Acetate-EDTA (TAE) buffers, and agarose were purchased from Gibco-BRL (Grand 
Island, U.S.A.). Plasma membrane and nuclear labelling kit were purchased from Life 
science, Australia. LysoTracker Red was purchased from Beyotime Biotechnology 
Company, China. Water used in all experiments was purified using a Milli-Q Plus 185 
water purification system (Millipore, Bedford, MA) with a resistivity higher than 18 
MΩ cm. 
Super-paramagnetic magnetite nanocrystal clusters 
Super-paramagnetic magnetite nanocrystal clusters (MNC) were synthesized 
according to a previous report.[1] Typically, 0.68 g of FeCl3·6H2O, 0.6 g of NaAc, and 
0.034 g of EDTA-2Na were dissolved in 20 mL of ethylene glycol. After sonication 
treatment in a water bath (Branson B5510-DTH) for 2 h, the dark yellow mixture was 
transferred to a Teflon-lined stainless-steel autoclave and heated at 200 °C for 8 h. 
After that, the black precipitate was rinsed with water and ethanol three times each 
and then dried at 50 °C in a vacuum oven. 
Magnetic nanocrystal clusters coated with large pore mesoporous silica 
Magnetic nanocrystal clusters coated with large pore mesoporous silica 
(MNC@LPMS) are synthesized through a modified two phase reaction method.[2, 3] 
The reaction was carried out in a three-neck reaction flask equipped with nitrogen 
flow and reflux condenser. Briefly, 20 mg of MNC was first dispersed in 20 ml of H2O 
with the aid of ultrasound. Then, the dispersion was added dropwise to 20 mL 
aqueous solution containing 0.4 g of CTAB and 100 mg of TEA under vigorous stirring. 
The mixture was further sonicated (Branson B5510-DTH) for 20 minutes and 
mechanical stirred for 1 hour. Afterwards, 50 µL of TEOS dissolved in 20 ml hexane 
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was added slowly. The system was allowed to react at 60 ˚C for 24 h in an oil bath. 
Afterwards, a brown solid product was collected by centrifugation and subject to 
surfactant extraction in 100 ml of ethanol containing 2 wt % ammonium nitrate for 
two cycles. To obtain amine functionalized product (MNC@LPMSA), 50 mg of 
surfactant-free MNC@LPMS was dispersed in 20 ml of toluene. Then, 100 µL of 
APTES was added and the mixture was refluxed at 80 °C for 24 h under nitrogen flow. 
Finally, MNC@LPMSA was obtained after centrifugation and washing repeatedly 
with toluene and ethanol. For comparison, magnetic nanocrystal clusters were also 
coated by silica shell with ordinary 2-3 nm mesoporous pore. The synthesis of these 
nanoparticles, denoted as MNC@MS, were the same as that for MNC@LPMS except 
that TEOS was added directly without hexane and the quantity was adjusted to 100 
µL. The MNC@MS was functionalized with APTES in the same way as MNC@LPMSA 
to obtain MNC@MSA. 
Loading capacity and protection of siRNA 
The siRNA loading and protection by MNC@LPMSA was evaluated by agarose gel 
electrophoresis. In the loading capacity assay, MNC@LPMSA and siRNA (0.2 µg) were 
mixed at different weight ratios from 5:1 to 200:1 (MNC@LPMSA to siRNA). After 
brief vortex, the mixture was incubated for 0.5 h at 4 °C to allow the formation of 
carrier/siRNA complex (MNC@LPMSA@siRNA). Then the complex was subjected to 
electrophoresis on an agarose gel (0.8% w/v) for 1 h at 60 V in TAE buffer. The 
resulting migration patterns were recorded under UV irradiation (G-BOX, SYNGENE). 
In the protection assay, 0.2 µg of siRNA that had been loaded into MNC@LPMSA 
with or without tannic acid coating was incubated with varied amounts of RNase at 
37 °C for 0.5 h. Then, 5 µL of sodium dodecyl sulfate (2 mg ml-1) was added to 
denature RNase A and stop the enzymatic reaction at 60 °C for 5 min. To further 
break the TA coating and displace the siRNA, 5 µL of poly(acrylic acid) (2 mg ml-1) was 
added and incubated for 10 min. The samples were subsequently analysed by 
agarose gel electrophoresis to determine the extent of siRNA degradation. 
Tannic acid coating and siRNA release 
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According to the loading capacity of MNC@LPMSA determined by gel 
electrophoresis, the final siRNA delivery system was obtained by coating the 
siRNA-loaded MNC@LPMSA with an acid-degradable tannic acid shell.[4, 5] First, 10 µL 
of siRNA (2 µg) was mixed with 10 µL of MNC@LPMSA (10 mg ml-1) in an Eppendorf 
tube and incubated for 30 min at 4 °C to form MNC@LPMSA@siRNA complex. Then, 
2.5 µL of AlCl3 (2.4 mM) and 2.5 µL of tannic acid (TA, 2.4 mM) solution were added 
and mixed thoroughly. After 1 minute, 25 µL of MOPS buffer (20 mM, pH=7) was 
added and the suspension was centrifuged to remove excess reactant. The resulting 
complex MNC@LPMSA@siRNA@TA was further washed with water twice and used 
for subsequent in vitro experiment. 
To study the degradation of the tannic acid layer, 10 mg of TA coated 
nanoparticles was incubated with 1 ml of either MOPS (pH=7) or MES (pH=5) buffer 
at 37 °C for desired periods. Then, the suspension was centrifuged. The supernatant 
liquid was diluted properly and adjusted to pH=2 with 1 M chloric acid to completely 
dissociate the TA/Al3+ complex. Then the TA concentration was determined using a 
calibration curve with a Uv-vis spectrometer (UV-2600, Shimadzu Corporation) at the 
wavelength of 275 nm. Note, due to the UV adsorption of siRNA near the 
wavelength, 2 wt% PAA was used as the model payload in this coating degradation 
experiment. The siRNA release was monitored by analyzing the residual siRNA in the 
solid carrier. The MNC@LPMSA@siRNA@TA complex (20 µg) was incubated in 1 ml 
of either MOPS (pH=7) or MES (pH=5) buffer at 37 °C for desired periods. Then, the 
suspension was centrifuged. The residual siRNA in the precipitate was replaced by 
poly(acrylic acid) and quantified by gel electrophoresis using GeneTools 4.03 
software. 
Cell culture and cell viability 
Human osteosarcoma cell line KHOS were purchased from ATCC (American Type 
Culture Collection) and grown in DMEM culture medium supplemented with 10% 
(v/v) fetal bovine serum (FBS) in a humidified 5% CO2 atmosphere at 37 °C. For all 
experiments, cells were harvested by using 0.25% trypsin and resuspended in fresh 
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medium before plating. The viability of cells was investigated using MTT assay. KHOS 
cells were seeded into 96-well plates at a density of 1 × 104 per well in 100 μL of 
media and grown for 24 h. Then, the growth medium was replaced with 100 μL of 
cell culture medium containing nanoparticles with or without siRNA loading. After 
incubation for 48 h, the medium was replaced by 100 μL of fresh medium and 10 μL 
of MTT (5.0 mg mL-1 in PBS) were added to each well. The cells were further 
incubated for 4 h. After that, the growth medium was removed and 150 μL of DMSO 
was added to each well to dissolve formazan crystals. Finally, the absorbance was 
determined using a micro-plate reader (Biotek, USA) at the wavelength of 595 nm. 
The viability of cells without nanoparticle treatment was assumed to be 100%. 
Cellular uptake by flow cytometry 
Quantification of cellular uptake was performed by flow cytometry analysis. KHOS 
cells were seeded in a 6-well plate (1×105 cells/well) and incubated for 24 h. Then, 
the cells were incubated with carrier/siRNA complex dispersed in culture medium 
(20 μg mL-1). To investigate the influence of magnetic field on the cellular uptake, 
another 6-well plate seeded with the same conditions was put on a 
neodymium–iron–boron (Nd–Fe–B) permanent magnet brick. After desired 
incubation time, the cells were washed twice with PBS and trypsinized. After 
centrifugation, the cells were resuspended in PBS containing trypan blue (200 μg 
mL-1). The fluorescence of endocytosed carrier/siRNA complex was detected by a 
FACSCalibur flow cytometer (Becton Dickinson) in FL1-H channel. The cellular uptake 
was calculated by the percentage of fluorescence-positive cells using the mock cells 
without siRNA treatment as negative control. For each sample, 1×104 cells were 
analysed at a rate of 200-400 cells per second. CellQuest 6.0 software was used for 
data analysis. 
Cellular uptake and subcellular location by confocal laser scanning 
microscopy (CLSM) 
The cellular uptake and subcellular location of carrier/siRNA complex were also 
observed with confocal laser scanning microscopy. KHOS cells were seeded in 6-well 
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plates (1×105 cells/well) with one piece of cover glass at the bottom of each well and 
cultured for 24 h. Then, the growth medium was changed to fresh medium 
containing nanoparticles (20 μg mL-1) loaded with FITC-labelled siRNA. After 6 h, the 
cells were washed twice with PBS and fixed with 4 wt % formaldehyde. The cell 
nucleus and plasma membrane were stained with Hoechst 33258 and Alexa Fluor® 
594 Wheat Germ Agglutinin (WGA), respectively. After the staining, the cells were 
softly washed twice with PBS to remove excessive dye and incubated in PBS before 
imaging. To investigate the effect of magnetic field on cellular uptake, another 6-well 
plate was put on the magnet brick with the other steps being the same as above. To 
investigate the endosome escape of gene carriers, samples with endosome and 
lysosome staining were also prepared. For these samples, LysoTracker Red was 
added to the culture medium 1 h before the fixation of cells following the supplier’s 
protocol. The cover glasses were visualized under a confocal laser scanning 
microscope (Leica Confocal 1P/FCS). Optical sections were averaged 4 times to 
reduce noise. Images were processed using Leica confocal software. 
Material characterization 
Transmission electron microscopy (TEM) images were taken with FEI Tecnai G2 
operated at 120 kV. The samples were prepared by dispersing the powder in ethanol 
and then dropped on carbon film supported by a Cu grid and air dried. Scanning 
electron microscopy (SEM) observation was carried out on a FEI Quanta 450 FEG 
environmental emission scanning electron microscope with energy dispersive X-ray 
(EDX) accessory. The samples were prepared by adding powder onto carbon tape 
and coated with platinum before SEM observation. The hydrodynamic size and 
zeta-potential of nanoparticles in aqueous dispersions were measured on a Malvern 
Zetasizer Nano ZS operated at a wavelength of 633 nm, where scattered light was 
collected at a fixed angle of 173°. X-ray diffraction (XRD) analysis was carried out on 
Rigaku Miniflex 600 with the Cu Kα line at 40 kV and 15 mA. Raman spectra were 
collected with HORIBA LabRAM HR Evolution with 633 nm laser. Fourier transform 
infrared (FTIR) spectra were recorded on a Thermo Scientific NICOLET 6700 FTIR 
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spectrometer with a Diamond ATR (attenuated total reflection) crystal. For each 
spectrum, 64 scans were collected at a resolution of 4 cm-1 over the range 650-4000 
cm-1. UV-vis absorption spectra were recorded on a UV-2600 spectrophotometer 
(Shimadzu Corporation). Thermogravimetric analysis (TGA) was performed on a 
Mettler Toledo Thermogravimetric Analyser, using an air atmosphere (60 mL min-1) 
with a heating ramp of 20 ˚C min-1. X-ray photoelectron spectroscopy (XPS) 
measurements were performed on an Axis Ultra (Kratos Analytical, UK) XPS 
spectrometer equipped with an Al Kα source (1486.6 eV). Nitrogen 
adsorption-desorption measurement was carried out at -196 ˚C using a TriStar II 
surface area and porosity analyser from Micromeritics. Prior to the measurement, 
the samples were degassed at 120 ˚C for 12 h. Brunauer-Emmett-Teller (BET) specific 
surface area was calculated using adsorption data at a relative pressure P/P0 range 
of 0.05-0.30. Pore size distribution was derived from adsorption branch of the 
isotherm using the Barrett-Joyner-Halenda (BJH) method. Pore volume was 
determined from the amount of N2 adsorbed at the single point of P/P0=0.99. 
Magnetic properties were measured by Quantum Design 9 T Physical Properties 
Measurement System (PPMS 9T) equipped with AC Measurement System (ACMS). 
Statistical analysis 
Quantitative data were reported as mean ± standard deviation (SD) of at least three 
independent experiments. The statistical analyses were performed using a two 
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II. Supplementary Figures and Tables 
 
Figure S1. Particle size distributions of (a) MNC and (b) MNC@LPMS from scanning 
electron microscopy images by analysing 100 nanoparticles. 
 
 
Figure S2. (a) Digital images of MNC@LPMS (1) and MNC (2) dispersed in water and 
(b) after 30 s under an external magnetic field. (c) Hydrodynamic particle size 
distributions of nanoparticles in water. 
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Figure S3. TEM images of hollow silica nanospheres with radial mesopores after 
etching MNC@LPMS with concentrated chloric acid. 
 
 
Figure S4. FTIR spectra of as prepared MNC@LPMS and after surfactant extraction 
with NH4NO3 for two times. The disappearance of C-H band in 2800-3000 cm
-1 range 
indicates the removal of CTAB. 
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Figure S5. FTIR spectra of MNC, MNC@LPMS and MNC@LPMSA. Spectra (b) is an 
enlarged part of spectra (a). For MNC@LPMS and MNC@LPMSA, the typical Si-O 
peaks at 800 cm-1 and 1040 cm-1 confirms silica coating. The peaks around 1630 cm-1 
are due to water absorbed. The shoulder around 1540 cm-1 for MNC@LPMSA is 
assigned to amine group. The broad peak around 1600 cm-1 for MNC is due to 
absorbed organic species during the hydrothermal synthesis. 
 
Figure S6. (a, b) TEM images, (c) nitrogen adsorption-desorption isotherms 
measured at -196 °C and (d) the corresponding pore size distributions of 
MNC@MSA. 
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Figure S7. (a) FTIR, (b) XPS spectra, (c) thermogravimetric (TG) and (d) derivative 
thermogravimetric (DTG) curves of MNC@LPMSA nanoparticles before and after 
tannic acid coating. For spectra clarity and cost reasons, the spectra (a, b) were 
recorded without cargo loading and the samples in (c, d) were loaded with 2 wt% 
PAA as model payload. 
In thermal analysis, the uncoated sample show major weight loss above 350 ˚C with 
two very broad DTG peaks around 380 ˚C and 450 ˚C. After tannic acid coating, the 
onset temperature for major weight loss is shifted lower to 280 ˚C and a more 
prominent DTG peak appears at 340 ˚C. The lower onset temperature for coated 
sample is consistent with the TG/DTG curves of tannic acid, which show a significant 
weight loss around 280 ˚C. 
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Figure S8. TEM images of MNC@LPMSA@siRNA@TA at different magnifications. 
 
Figure S9. (a) UV-vis spectra and (b) calibration curve of TA. (c) pH-dependent 
disassembly of TA from nanoparticles. (d) the molecule structure of TA and the 
scheme of its pH-dependent assembly with Al3+ ion. 
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Figure S10. (a) MNC@LPMSA@siRNA@TA was incubated at different pH buffers for 
24 h and 48 h. The residual siRNA was analysed by gel electrophoresis. (b) Residual 




Figure S11. Hydrodynamic particle size distributions of (a) siRNA loaded 
nanoparticles in water and (b) MNC@LPMSA@siRNA@TA in in cell culture medium 
(DMEM) containing 10 % serum (FBS) for different periods. The small peaks below 
100 nm and above 5000 nm in (b) are due to proteins and impurities in serum, 
respectively. 
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Figure S12. Flow cytometry analysis of KHOS cells incubated in culture medium 
containing 20 µg ml-1 MNC@LPMSA@siRNA@TA after different time periods with or 
without magnetic field (MF). The cells incubated in blank culture medium were used 
as the control. The histograms show distribution of events on the FITC (FL1) channel. 
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Figure S13. CLSM images of KHOS cells after 12 h of incubation with 20 µg ml-1 
MNC@LPMSA@siRNA@TA complex under a magnetic field. (Ⅰ) cell nucleus (blue) 
labelled with Hoechst 33258; (Ⅱ) siRNA (green) was labelled with FITC; (Ⅲ) 
endosome (red) labelled with LysoTracker Red; (Ⅳ) overlay image of (Ⅰ), (Ⅱ) and 
(Ⅲ). Panel (b) is the high magnification image of the circle part in panel (a). The 
location overlap of siRNA signal and endosome signal is indicated by orange colour. 
 
 
Table S1. Elemental composition (atom %) derived from X-ray photoelectron 
spectroscopy 
Sample O C Si 
MNC@LPMSA 57.88 13.35 28.77 
MNC@LPMSA@TA 50.78 35.23 13.99 
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Chapter 6 Mesoporous Organosilica Nano-bowl with 
High DNA Loading Capacity – a Potential Gene Delivery 
Carrier 
6.1 Introduction, Significance and Commentary 
Gene therapy is one of the most promising therapeutic strategies for treating various 
diseases. The successful gene therapy strongly relies on the development of efficient 
delivery carrier. Mesoporous silica based nanocomposites, as one type of non-viral 
delivery system, have unique advantages in terms of biocompatibility and 
preparation cost. However, the loading capacity of silica based nanocomposites is 
usually limited by the fact that large gene molecules, especially double-stranded 
DNA, can hardly enter into the mesopores of traditional mesoporous silica 
nanoparticles. 
 In this work, we report for the first time the synthesis of mesoporous 
organosilica nanoparticles with novel bowl-like morphology. Their application 
potential as a high-loading gene delivery carrier is demonstrated by DNA transfection 
in vitro. The highlights and novelty of this work include: 
1. Mesoporous organosilica nanoparticles with novel bowl-like morphology. 
 Bowl-like mesoporous organosilica nanoparticles were prepared for the first 
time by a simple “hard templating followed by hydrothermal etching” method. 
These non-aggregated nano-bowls show uniform particle sizes around 180 nm and 
open cavities of about 140 nm in the centre, which is especially suitable for 
accommodating very large guest species. The synthesis procedure is characterized 
step-by-step and a clear synthesis mechanism is given. 
2. Nano-bowls with high DNA loading and delivery capacity. 
 After amine functionalization, these mesoporous organosilica nano-bowls show 
significantly higher loading capability for plasmid DNA than traditional (hollow, 
dendric, MCM41 type) silica-based nanoparticles thanks to their large accessible 
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center cavity. Furthermore, after co-loading with an endosomolytic reagent in the 
mesopores, enhanced transfection efficiency comparable to polymer standard was 
achieved for in vitro plasmid DNA transfection. 
6.2 Mesoporous Organosilica Nano-bowl with High DNA Loading 
Capacity – a Potential Gene Delivery Carrier 
This section is included in the thesis as it appears as a paper published by L. Xiong 
and S.-Z. Qiao. A Mesoporous Organosilica Nano-bowl with High DNA Loading 
Capacity – a Potential Gene Delivery Carrier, Nanoscale, 2016, 8, 17446. 
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6.3 Supplementary Information 
This section is included in the thesis as supplementary information to section 6.2. It 
includes additional information which is not put in the main text of the published 
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Tetraethyl orthosilicate (TEOS), (3-Aminopropyl)-triethoxysilane (APTES), 1, 
2-Bis(triethoxysilyl)ethane (BTEE), cetyltrimethylammonium bromide (CTAB), 
ammonia solution (25 wt %), cetyltrimethylammonium tosylate (CTAT), 
triethanolamine (TEA), ammonium nitrate, toluene, ethanol, fluorescein 
isothiocyanate (FITC), 3-[4,5-dimethylthialzol-2-yl]-2,5-diphenyltetrazolium bromide 
(MTT), sodium hydroxide, ethylenediaminetetraacetic acid (EDTA), 
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Tris(hydroxymethyl)aminomethane (Tris), methylsulfoxide (DMSO), 
polyethylenimine (PEI, 25 kDa) and deoxyribonuclease I (DNase I) were purchased 
from Sigma Aldrich. Dulbecco's Modified Eagle's Medium (DMEM), fetal bovine 
serum (FBS), and phosphate buffered saline (PBS), trypsin, Tris Acetate-EDTA (TAE) 
buffers, and agarose were purchased from Gibco-BRL (Grand Island, U.S.A.). Gel Red 
(10000x in water) was purchased from Biotium, Australia. Gel loading dye blue (6x) 
was purchased from Biolab, Australia. Water used in all experiments was purified 
using a Milli-Q Plus 185 water purification system (Millipore, Bedford, MA) with a 
resistivity higher than 18 MΩ cm. 
Synthesis of silica nanospheres 
Silica nanospheres (denoted as SS) with sizes around 160 nm were prepared by the 
Stöber method. Briefly, ethanol (20 mL), H2O (1 mL), and ammonia solution (25 wt %, 
1 mL) were combined at 40 °C under stirring. Then, TEOS (1 mL) was added and 
stirred for another 8 h at 40 °C. 
Synthesis of mesoporous organosilica nano-bowls 
The SS was then coated with an organosilica layer to obtain core-shell particle 
(denoted as SS@OS). The above Stöber reaction mixture (2 mL) was added to a 
solution containing water (75 mL), ethanol (5 mL), CTAB (150 mg) and ammonia (25 
wt %, 1 mL). After stirring at room temperature for 0.5 h, a total of BTEE (30 µL) 
dissolved in ethanol (3 ml) was added in 3 times at 10 min intervals. After reaction 
for another 24 h, the SS@OS product was collected by centrifugation and washed 
with ethanol and water for several times. 
Mesoporous organosilica nano-bowl (denoted as Bowl) was obtained after 
removing the core part of the SS@OS by a hydrothermal-etching method.[1] The 
washed SS@OS was redispersed in a solution containing water (20 mL), Na2SO4 (80 
mg) by sonication. Then, the dispersion was adjust to pH 3 with H2SO4 (0.1 M) and 
stirred at room temperature for 24 h. Afterwards, the mixture was transferred into a 
sealed autoclave and heated at 180 °C for 10 h. The etched particles were 
centrifuged and washed with water for several times. 
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Synthesis of hollow mesoporous organosilica nanoparticles 
Hollow mesoporous organosilica nanoparticles (denoted as Hollow) were prepared 
according to the literature with slight modification.[2] The above Stöber silica solution 
was further mixed with H2O (20 mL), CTAB (150 mg) and ammonia solution (0.5 
mL).Then, BTEE (0.5 mL) was added and the mixture was allowed to react for 6 h at 
30 °C. The particles were collected by centrifugation and redispersed into Na2CO3 
aqueous solution (0.6 M). After stirring at 80 °C for 1 h, the hollow particles were 
centrifuged and washed with water for several times. 
Synthesis of MCM-41 type nanoparticles 
MCM-41 type mesoporous silica nanoparticles (denoted as MCM41) were prepared 
according to the literature.[3] Sodium hydroxide aqueous solution (2 M, 0.7 mL) was 
added to water (96 mL) containing CTAB (0.2 g) at 80 °C. Then, TEOS (1 mL) was 
added under vigorous stirring. The mixture was allowed to react for 2 h at 80 °C and 
then centrifuged to get the precipitate. The white precipitate was washed with 
water for several times. 
Synthesis of dendric mesoporous silica nanoparticles 
Dendric type mesoporous silica nanoparticles (denoted as Dendric) were prepared 
according to the literature.[4] CTAT (0.48 g) and TEA (87 mg) was dissolved in water 
(25 mL) at 80 °C. Then, TEOS (4.9 mL) was added under vigorous stirring. The mixture 
was allowed to react for 2 h at 80 °C and then centrifuged to get the precipitate. The 
white precipitate was washed with water for several times. 
Surfactant removal, amine functionalization and fluorescence labeling 
The surfactant in the above as-prepared product was removed by extraction for two 
cycles. In each cycle, the as-prepared powder (50 mg) was refluxed in ethanol 
solution (10 mL) containing ammonium nitrate (2 wt %) for 6 h. For amine 
functionalization, the extracted powders were refluxed in toluene (20 mL) containing 
APTES (50 µL) at 90 °C for 12 h followed by washing sequentially with toluene and 
ethanol. The amine functionalized products are denoted with a prefix A for each type 
of particles. For example, A-Bowl stands for amine functionalized organosilica 
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nano-bowls. For fluorescence labelling, A-Bowl (10 mg) were stirred in ethanol 
solution of FITC (5 mL, 10 µg mL-1) in dark for 24 h at room temperature. The labelled 
nanoparticles were collected by centrifugation and washed with ethanol repeatedly 
until the supernatants were colourless. 
Cell culture 
Human embryonic kidney 293 (HEK293) cells  were purchased from American Type 
Culture Collection and grown in DMEM culture medium supplemented with 10% (v/v) 
FBS in a humidified 5% CO2 atmosphere at 37 °C. For all experiments, cells were 
harvested by using 0.25% trypsin and resuspended in fresh medium before plating. 
Cytotoxicity assay 
HEK293 cells were seeded into 96-well plates at a density of 1 × 104 per well in 
culture medium (100 μL) and grown for 24 h. Then, the medium was replaced by 
ones containing varied concentrations of nanoparticles. After 24 h incubation, the 
medium was replaced by fresh medium and 10 μL of MTT (5.0 mg mL-1 in PBS) was 
added to each well. After further incubation for 4 h, the medium was removed and 
150 μL of DMSO was added to each well to dissolve formazan crystals. Finally, the 
absorbance was determined using a micro-plate reader (Biotek, USA) at the 
wavelength of 595 nm. The viability of cells without nanoparticle treatment was 
assumed to be 100%. Data were expressed as mean ± standard deviation (SD) of at 
least three independent experiments. 
Plasmid DNA preparation 
The pEGFP-N1 plasmid DNA (pDNA, 4.7kb) expressing the enhanced green 
fluorescent protein (EGFP) was prepared in Escherichia coli DH5α strain and 
extracted using a QIAGEN Plasmid Midi kit (QIAGEN, Hilden, Germany) according to 
the manufacturer's protocol. The integrity and purity of the prepared pDNA was 
analyzed using 0.8% agarose gel electrophoresis and the pDNA concentration was 
determined using a nanophotometer (P300, Implen GmbH). For microscopy imaging 
experiment, the pDNA was further labelled by fluorescent dye (YOYO-1) at a molar 
ratio of 1 molecular dye to 100 nucleic acid base pairs. 
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Gel retardation assay 
The binding capability of nanoparticles for pDNA was evaluated by agarose gel 
electrophoresis. Samples were prepared by mixing nanoparticles and pDNA (0.2 µg) 
at different weight ratios and incubated for 30 min at room temperature. After the 
addition of gel loading dye blue, the samples were electrophoresed through a 0.8% 
agarose gel containing gel red in TAE buffer solution at 60 V for 60-90 min. The 
resulting pDNA migration patterns were recorded under UV irradiation (G-BOX, 
SYNGENE). To evaluate the DNA protection capability, the nanoparticles and pDNA 
were mixed at a weight ratio of 20 and incubated for 30 min at room temperature. 
Then, 2.5 U of DNase I (0.5 U μL-1) in 10mM Tris-HCl, 2.5 mM MgCl2, 0.5 mM CaCl2  
solution (pH 7.6) was added and the mixture was further incubated at 37 °C for 30 
min. The DNase I was inactivated by adding 500 mM EDTA (2 μL). The pDNA was 
then released from the complex by treatment with heparin (10 mg mL-1) for 30 min. 
Naked pDNA was also treated in the same procedure as the control. 
In vitro transfection 
HEK293 cells were seeded into a 24-well plate with coverslips at the density of 2× 104 
cells per well in culture medium (400 μL) 24 h before transfection. Prior to 
transfection, nanoparticle/pDNA complexes were freshly prepared by mixing pDNA 
(0.4 µg) and A-Bowl (8 µg) in water (20 μL).The mixture was incubated for 30 min at 
room temperature and then diluted with 400 μL DMEM media. The cells were 
incubated with this particle/pDNA suspension for 4 h and then the medium was 
replaced by DMEM containing 10% FBS. After 48 h, the transfection results was 
observed using a fluorescence microscope (Zeiss Axio Vert. A1) equipped with a 488 
nm laser and the transfection efficiency was evaluated using a flow cytometry 
(Becton Dickinson) in FL1-H channel. For co-delivery of pDNA and cholorquine, 
A-Bowl (2 mg) was first incubated with cholorquine aqueous solution (200 µg mL-1, 1 
mL) for 24 h, then the suspension was centrifuged and the precipitate was washed 
with water twice. The amount of loaded cholorquine was determined by the UV–vis 
absorption of super liquid at the wavelength of 329 nm before and after 
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incubation.[5] Then, the cholorquine-loaded A-Bowl was mixed with pDNA following 
the process described above and used for subsequent transfection. For transfection 
mediated by PEI, pDNA (0.4 µg) in 50 μL DMEM was mixed with PEI (2 µg) in 50 μL 
DMEM. After incubation for 30 min at room temperature, the mixture was diluted 
with 300 μL DMEM and used for subsequent transfection. The delivery of pDNA and 
its subcellular location were also observed using a Leica SP5 confocal laser scanning 
microscope. HEK293 cells were fixed with 4 wt % formaldehyde at 16 h after 
transfection with the particle/YOYO-1-labelled pDNA complex. The cell nucleus and 
plasma membrane were stained with Hoechst 33258 (1 µg mL-1) and Alexa Fluor 594 
Wheat Germ Agglutinin (WGA, 5 µg mL-1) for 15 min at room temperature, 
respectively. After the staining, the cells were softly washed twice with PBS to 
remove excessive dye and incubated in PBS before imaging. 
Material characterization 
Transmission electron microscopy (TEM) images were taken with FEI Tecnai G2 
operated at 120 kV. The samples were prepared by dispersing the powder in ethanol 
and then dropped on carbon film supported by a Cu grid and air dried. Scanning 
electron microscopy (SEM) observation was carried out on a FEI Quanta 450 FEG 
environmental emission scanning electron microscope. The samples were prepared 
by adding powder onto carbon tape and coated with platinum before SEM 
observation. The hydrodynamic size and zeta-potential of nanoparticles in aqueous 
dispersions were measured on a Malvern Zetasizer Nano ZS operated at a 
wavelength of 633 nm, where scattered light was collected at a fixed angle of 173°. 
Raman spectra were collected with HORIBA LabRAM HR Evolution with 633 nm laser. 
Fourier transform infrared (FTIR) spectra were recorded on a Thermo Scientific 
NICOLET 6700 FTIR spectrometer with a Diamond ATR (attenuated total reflection) 
crystal. For each spectrum, 64 scans were collected at a resolution of 4 cm-1 over the 
range 400-4000 cm-1. UV-vis absorption spectra were recorded on a UV-2600 
spectrophotometer (Shimadzu Corporation). Thermogravimetric analysis (TGA) and 
differential scanning calorimetry (DSC) was performed on a Mettler Toledo 
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Thermogravimetric Analyser, using an air atmosphere (60 mL min-1) with a heating 
ramp of 20 ˚C min-1. Nitrogen sorption measurement was carried out at -196 ˚C using 
a TriStar II surface area and porosity analyser (Micromeritics). Prior to the 
measurement, the samples were degassed at 120 ˚C for 12 h. 
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Supporting Data 
 
Fig. S1 SEM (a, b) and TEM (c, d) images of SS (a, c) and SS@OS (b, d). The positions 
of two SS cores in SS@OS (d) are circled with dotted-line to illustrate the asymmetric 




Fig. S2 Hydrodynamic size distributions of nanoparticles dispersed in water. 
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Fig. S3 SEM images of products after hydrothermal treatment when the BTEE 
addition is (a) 10 µL and (b) 50 µL. SEM images of products when (c) 30 µL BTEE is 
added over a period of 6 h, the Janus part is indicated with black arrow, (d) SS@OS is 




Fig. S4 SEM images of amine functionalized mesoporous organosilica nano-bowls. 
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Fig. S6 SEM (a, b, c) and TEM (d, e, f) images of A-MCM41 (a, d), A-Dendric (b, e) and 
A-hollow (c, f). The scale bars in (a, b, c) and (d, e, f) are 1 µm and 100 nm, 
respectively. 
 




Fig. S7 Nitrogen sorption and pore size distribution (insert) curves of (a) A-MCM41, 
(b) A-Hollow, (c) A-Dendric and (d) A-SS. 
 




Fig. S8 Gel retardation assays of nanoparticles/pDNA complex at different 




Fig. S9. Proposed loading status of plasmid DNA on various amine functionalized 
silica-based nanoparticles: (Ⅰ) A-Bowl, (Ⅱ) A-Hollow, (Ⅲ) A-Dendric, (Ⅳ) A-MCM41, 
(V) A-SS. 
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Fig. S10 TEM images of A-Bow (a) before and (b) after loading of pDNA. The scale bar 





Fig. S11. (a) Viability of HEK293 cells after 24 h incubation with A-Bowl or A-Bowl 
containing 4 % chloroquine. (b) Confocal images of HEK293 cells after 4 h incubation 
with 20 µg ml-1 A-Bowl. (Ⅰ) cell nucleus (blue) labelled with Hoechst 33258; (Ⅱ) 
differential interference contrast image; (Ⅲ) A-Bowl particles (green) labeled with 
FITC; (Ⅳ) overlay image of (Ⅰ), (Ⅱ) and (Ⅲ). 
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Fig. S12. Fluorescent and bright field images of HEK293 cells transfected with 
different transfection reagents. 
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Table S1. Hydrodynamic diameters of nanoparticles dispersed in water. 
Sample Average Particle Size (nm) Polydispersity Index 
SS 196 0.036 
SS@OS 268 0.042 
Bowl 207 0.178 
A-Bowl 240 0.218 
 
Table S2. Structure parameters of nanoparticles. 
Sample 









) (nm) (mmol g
-1) 
Bowl 985 1.08 2.5 - 
A-Bowl 876 0.97 2.1 0.81 
A-MCM41 754 0.59 2.0 1.69 
A-Dendric 234 0.91 17.2 1.24 
A-Hollow 852 0.95 2.0 0.93 
A-SS 31 0.09 - 0.11 
a) Brunauer-Emmett-Teller (BET) specific surface area was calculated using N2 
adsorption data at a relative pressure P/P0 range of 0.05-0.30. b) Pore size 
distribution was derived from adsorption branch of the isotherm using the 
Barrett-Joyner-Halenda (BJH) method. c) Pore volume was determined from the 
amount of N2 adsorbed at the single point of P/P0=0.99. d) Surface amine group was 
calculated from the difference of weight loss in thermogravimetry between modified 
and unmodified samples.
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Chapter 7 Conclusion and Perspective 
7.1 Conclusion 
The researches in this thesis are aimed at developing a serial of novel mesoporous 
silica nanocomposites with favorable structure and surface functionalization for drug 
and gene delivery. Based on these studies, the following results have been obtained: 
 (1) We firstly studied the controllable synthesis of stellate mesoporous silica 
nanoparticles with radial pore morphology. For the delivery application, a precise 
control over the particle size and the pore structure of the material is highly 
desirable, because these properties affect the bio-distribution, cellular uptake, drug 
release profile, and loading capacity of the nanocarrier. Therefore, we conducted 
systematic study to elucidate the effects of synthesis conditions (including reaction 
temperature and time, and reagent ratio) on the final particle product. It was found 
that the formation of stellate particles is a two-phase process and the reaction 
kinetics plays an important role in determining the structure parameters. The 
particle size of the material could be tailored continuously ranging from 50 to 140 
nm and the pore size from 2 to 20 nm. After further functionalization with low 
molecular weight poly(ethyleneimine), these nanocomposites demonstrated good 
capability for intracellular delivery of the anticancer drug doxorubicin. 
 (2) Then, we developed a cancer cell-specific nuclear-targeted delivery system 
based on mesoporous silica nanoparticles. To minimize the side effects of highly 
toxic anticancer drugs, it is necessary to deliver the drugs selectively into cancer cells. 
Meanwhile, for many anticancer drugs, the cell nucleus is the sub-cellular organelle 
where they exert their anticancer effect. Therefore, we modified the 40 nm 
mesoporous silica nanoparticles with two biologic targeting moieties, folic acid and 
dexamethasone, to selectively deliver anticancer drugs in to the nucleus of cancer 
cells. The results suggest this strategy can not only enhance the inhibition efficacy of 
doxorubicin on cancerous Hela cells through active nucleus accumulation but also 
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reduce toxic side effects on normal cells though receptor-mediated selective cellular 
uptake. 
 (3) Next, we developed magnetic core–shell silica nanoparticles with large radial 
mesopores for small interfering RNA (siRNA) delivery. Delivery of siRNA is an 
emerging technology to treat various diseases by halting the production of target 
proteins. As the naked siRNA molecule is susceptible to enzyme degradation and 
cannot cross the cell membrane, we prepared 150 nm magnetic core–shell silica 
nanoparticles with large radial mesopores to load the siRNA inside the mesopores. 
These nanoparticles possess both high loading capacity of siRNA and strong 
magnetic response under an external magnetic field. Furthermore, an acid-liable 
coating composed of tannic acid was applied to further protect the loaded siRNA. 
The coating also increased the dispersion stability of the siRNA-loaded carrier and 
served as a pH-responsive releasing switch. Using these nanocarriers, enhanced 
delivery of functional siRNA into human osteosarcoma cancer cells was achieved 
with the aid of the external magnetic field. 
 (4) Finally, we prepared bowl-like mesoporous organosilica nanoparticles for 
plasmid DNA delivery. Due to the much larger size of plasmid DNA than siRNA, a 
specific nanostructure distinct from traditional mesoporous silica nanoparticles 
needs to be developed for DNA delivery. Therefore, we fabricated 180 nm 
organosilica nanoparticles with a novel bowl-like structure, which can load DNA 
molecules in the central bowl cavity. Under the same amine functionalization, these 
nano-bowls showed significantly higher loading capacity for plasmid DNA than 
traditional (hollow, dendric, MCM41 type) silica-based nanocarriers thanks to their 
large accessible center cavity. Furthermore, after co-loading with an endosomolytic 
reagent in the mesopores, enhanced transfection efficiency comparable to the 
polymer standard was achieved for in vitro plasmid DNA transfection. 
 In summary, these findings have demonstrated the design and fabrication of 
several novel silica nanocomposties for drug and gene delivery, and may pave a way 
of the further development of silica-based delivery system. 
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7.2 Perspective 
Based on the work presented in this thesis, we propose that future studies can be 
carried out in the following directions: 
 1) Synthesis of stellate mesoporous organosilica nanoparticles. In chapter 3, 
tunable synthesis of stellate mesoporous silica nanoparticles with radial pore 
morphology was demonstrated using a weak base triethanolamine as the catalyst in 
a two phase reaction system. It would be interesting to investigate whether similar 
reaction conditions can be applied to the controllable synthesis of stellate 
mesoporous organosilica nanoparticles. Due to the versatile organic groups 
incorporated in their silica framework, stellate mesoporous organosilica silica 
nanoparticles may exhibit some unique properties for drug delivery and other 
applications. 
 2) Bioactive molecules modified mesoporous silica nanoparticles. In chapter 4, 
cancer cell-specific nuclear-targeted delivery was achieved by mesoporous silica 
nanoparticles modified simultaneously with two bioactive small molecules. This 
illustrates the importance of combining biologically active components with 
relatively inert mesoporous silica structure for efficient drug delivery. With the 
convergence of nanotechnology and molecular biology, we anticipate that more 
bioactive molecules such as aptamers and antibodies will be exploited in 
mesoporous silica nanocomposite delivery systems. 
 3) Multifunctional large-pore core-shell mesoporous silica nanoparticles. In 
chapter 5, core–shell silica nanoparticles with large radial mesopores were prepared 
for magnetically-targeted siRNA delivery. Due to the intrinsic multifunctionality of 
the magnetite core, these core-shell nanoparticles could be further explored for 
magnetic resonance imaging (MRI) or hypothermia therapy. Furthermore, using 
similar synthesis method, the magnetic core component could be replaced with 
other functional materials like gold or carbon nanospheres. Thus, other types of 
multifunctional large-pore core-shell mesoporous silica nanoparticles could be 
developed. 
 
 142  
 4) Functional bowl-like nanoparticles. In chapter 6, we prepared bowl-like 
mesoporous organosilica nanoparticles for DNA delivery. However, only simple 
amine functionalization was carried out for comparison purpose. We anticipate more 
complex nanostructure could be constructed based on these nano-bowls through 
elaborate functionalization. For example, a bowl cover may be fabricated to seal the 
cargo loaded in the bowl cavity. In another possible and interesting aspect, these 
organosilica nano-bowls could be transformed into carbon nano-bowls through 
thermal carbonization and used in delivery and catalysis applications. 
 5) In vivo delivery evaluation. In this project, the silica nanocomposites are only 
evaluated for drug and gene delivery in vitro. For the ultimate goal of clinical 
translation, systematic in vivo evaluations are essential. Because many additional 
biological barriers such as blood compatibility, reticuloendothelial system and kidney 
filtration exist in the body environment, the delivery results of these silica 
nanocomposites in vivo can be significantly different from that in vitro. Therefore, 
more material engineering may be needed for these silica nanocomposites based on 
the results of in vivo evaluation. 
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